The storylines故事线
Click a development’s source links to open the original article.点击进展下方的来源链接可打开原文。
Strategic cooperation MoUs战略合作备忘录
11 · 2024-01-05 → 2026-06-06
▾
Signing of strategic cooperation agreements with governments, hospitals, and companies for supply chain, healthcare, and TCM projects.与政府、医院及企业签署供应链、医疗健康及中药项目的战略合作协议。
2024-01-05Mai Nuo Wei Medicine completed Pre-B round financing co-led by Bishuiquan Fund and Jointown Venture Capital, with existing shareholder Wenzhou Investment following on; also signed strategic cooperation framework agreement with Jointown Pharmaceutical Group.迈诺威医药完成Pre-B轮融资，由碧水泉基金和九州通创投共同领投，原有股东文周投资跟投；同时与九州通医药集团签订战略合作框架协议。
2024-03-26Ezhou City People's Government and Jointown Pharmaceutical Group signed a supply chain project cooperation agreement, following the Jointown Wotian International Supply Chain Center project, marking another milestone in Ezhou.鄂州市人民政府与九州通医药集团签署供应链项目合作协议，继九州通沃田国际供应链中心项目后又一里程碑。
2024-06-11Jointown signed a pharmaceutical industry chain project agreement with Tongchuan District, Dazhou City, for local cooperation in medical supply chain projects.九州通与达州市通川区签署医药产业链项目签约仪式，推进当地医药供应链合作。
2024-09-03Jointown Health Technology Group formed a strategic partnership with Ping An Health (Ping An Good Doctor) to build an 'Internet + medical + pharmaceutical' service chain.九州通健康科技集团与平安健康（平安好医生）达成战略合作，共同打造“互联网+医疗+医药”服务链。
2024-11-28Signed strategic cooperation agreement with Jeonggwanjang (正官庄) on Chinese herbal medicine slices, leveraging Jiuzhoutong's distribution channels.与正官庄签署战略合作协议，在中药饮片领域展开合作，借助九州通渠道资源。
2025-04-02Jointown (via Shanghai Haoyao Pharmacy chain) and Beijing Tongrentang jointly established Beijing Tongrentang (Shanghai) Pharmaceutical Co., Ltd., registered capital 30 million yuan, covering drug wholesale/retail and TCM decoction services.九州通（通过上海好药师大药房）与北京同仁堂共同成立北京同仁堂（上海）医药有限公司，注册资本3000万元，经营药品批发零售及中药饮片代煎服务。
2025-11-01Signed an investment agreement with Xiangyang City government to invest 500 million yuan in 6 sub-projects including pharmaceutical distribution scale upgrade, medical device production and sales integration, and digital medical insurance service center pilot.与襄阳市政府签约，投资5亿元建设医药流通规模提升、医疗器械产销一体化、数智化三医便民服务中心试点等6个子项目。
2026-03-20Signed a strategic cooperation framework agreement with the Qianjiang municipal government for investment and development in health industry.与潜江市政府签订战略合作框架协议，投资发展卫生健康事业。
2026-04-11Signed a strategic cooperation framework agreement with Guyuan City, Ningxia, focusing on upgrading the 'Gu Shiyi' authentic Chinese medicinal materials industry chain and smart healthcare services.与宁夏固原市签署战略合作框架协议，围绕‘固十味’道地中药材产业升级和智慧医疗服务等领域开展合作。
2026-04-15Signed a strategic cooperation framework agreement with Macheng City government to boost the Dabie Mountains medical and health industry, focusing on TCM industry chain development.与麻城市人民政府签署战略合作框架协议，助力大别山医药健康产业高质量发展，聚焦中医药产业链。
2026-06-06Jointown held talks with Hainan Medical University and Haikou International Investment Promotion Bureau to jointly build a big health industry collaborative innovation platform, moving from planning to implementation.九州通与海南医科大学、海口国际投资促进局举行座谈会，三方就共建大健康产业协同创新平台达成战略合作意向，从谋划进入实际落地阶段。
Partnerships with medical device companies与医疗器械公司的合作
9 · 2024-01-11 → 2026-05-14
▾
Strategic cooperation with Yuyue Medical, Omron, Autobio, KDL, and others, expanding medical device distribution.与鱼跃医疗、欧姆龙、安图生物、康德莱等战略合作，扩大医疗器械分销。
2024-01-11Jointown signed 2024 strategic cooperation agreement with Yuyue Medical (鱼跃医疗) at its new headquarters in Wuhan, continuing a 16-year partnership.九州通与鱼跃医疗在武汉新总部签订2024年战略合作协议，延续16年合作。
2024-01-29Jointown signed 2024 strategic cooperation agreement with Omron at its Wuhan headquarters, extending a 15-year partnership; plans to expand county-level markets and strengthen OTC channels.九州通与欧姆龙在武汉总部签订2024年战略合作协议，延续15年合作；计划拓展县域市场并加强OTC渠道。
2024-05-17Medical device agency brand promotion revenue in 2023 reached 8.888 billion yuan (+31.44% YoY), representing 594 SKUs from 8 manufacturers including Johnson & Johnson, Abbott, Fresenius, Roche, Mammotome.2023年医疗器械总代品牌推广业务收入达88.88亿元（同比增长31.44%），代理强生、雅培、费森尤斯、罗氏、麦默通等8家厂家594个品规。
2024-07-01Greenland Holdings established Greenland Medical Industry Group and signed strategic cooperation agreements with Jointown and United Imaging Healthcare to cooperate on centralized medical device distribution and hospital SPD business in Shanghai.绿地控股成立绿地医疗产业集团，与九州通、联影医疗签署战略合作协议，在上海合作开展医疗器械集中配送和医院SPD业务。
2024-10-31Jointown's medical device segment revenue reached 24.712 billion yuan in the first three quarters of 2024, maintaining a leading industry position; the company cooperates with over 60% of top 100 global multinational enterprises and over 80% of top 100 domestic industrial enterprises.九州通2024年前三季度医疗器械板块实现销售收入247.12亿元，稳居行业前列；公司与全球60%以上100强跨国企业、国内80%以上100强工业企业开展业务合作。
2024-11-07Medical device total-distribution: 1,128 SKUs as of Sep 2024, 10 products with >100 million sales; new partnerships with Jiaqi, Dentsply Sirona, Salubris, ConvaTec.医疗器械总代总销：截至2024年9月品规1128个，10个过亿品规；新开发加奇、登士柏、信立泰、康维德等品牌合作。
2025-07-15Jointown signed a strategic cooperation agreement with Autobio Diagnostics (Zhengzhou Antu Bioengineering) at Antu's IVD industrial park, aiming to leverage Jointown's distribution network and digital tech to promote Autobio's IVD products.九州通与郑州安图生物工程股份有限公司在安图生物体外诊断产业园签署战略合作协议，旨在借助九州通的流通网络和数字化技术推广安图生物的体外诊断产品。
2026-03-11Signed a comprehensive strategic cooperation agreement with KDL (Shanghai) Medical Instrument Co., Ltd., covering product supply, logistics, terminal marketing, digital services, and medical-industrial innovation.与康德莱医疗器械股份有限公司签署全面战略合作协议，涵盖产品供应、物流配送、终端营销、数字化服务及医工创新等领域。
2026-05-14Medical device segment revenue in 2025 reached 39.279 billion yuan, up 15.91% YoY. Strategic partnerships formed with Yuwell, Sinocare, Kefumei, Durex, Xiaolu Mama, etc. Online business grew over 30% YoY under national trade-in subsidy policy.2025年医疗器械板块销售收入392.79亿元，同比增长15.91%。与鱼跃、三诺、可复美、杜蕾斯、小鹿妈妈等品牌达成战略合作，线上业务在国补政策下同比增速超30%。
Hubei Jiuzhou Pharmaceutical Supply Chain Platform湖北九州医药供应链平台
3 · 2024-01-11 → 2025-08-11
▾
State-backed third-party digital supply chain platform launched as Hubei's first provincial-level pharma supply chain platform.国资背景的第三方数字供应链平台上线，成为湖北首个省级医药供应链平台。
2024-01-11Hubei Jiuzhou Pharmaceutical Supply Chain Co., Ltd. was inaugurated in Wuhan, a state-backed third-party digital supply chain platform for the pharmaceutical industry.湖北九州医药供应链有限公司在武汉揭牌成立，为国资背景的第三方医药产业数字化供应链综合服务平台。
2024-04-11The Hubei Jiuzhou Pharmaceutical Supply Chain Digital Integrated Service Platform, built by Jointown, was officially launched as the first provincial-level pharmaceutical supply chain platform in Hubei, integrating upstream and downstream information.由九州通参与建设的湖北九州医药供应链数字化综合服务平台正式上线，成为湖北省首家省级医药供应链平台，集成上下游信息。
2025-08-11Hubei Jiuyuan Supply Chain Co., Ltd. was established, registered capital 50 million RMB, wholly owned by Hubei Jiuzhou Pharmaceutical Supply Chain Co., Ltd., which is jointly held by Hubei Commerce Logistics Group and Jointown.湖北久源供应链有限公司成立，注册资本5000万元，由湖北九州医药供应链有限公司全资持股，后者由湖北商贸物流集团有限公司、九州通等共同持股。
Subsidiary guarantee disclosures子公司担保披露
12 · 2024-01-16 → 2025-12-13
▾
Regular monthly disclosures of new guarantees and outstanding guarantee balances for subsidiaries.定期月度披露为子公司新增担保及担保余额。
2024-01-16Jointown disclosed that in December 2023 it added 1.981 billion yuan in guarantees for subsidiaries, with total guarantee balance reaching 25.1 billion yuan.九州通披露2023年12月新增子公司担保19.81亿元，担保余额达251亿元。
2024-02-21Jiuzhou Tong disclosed that in January 2024 it added 2.85 billion yuan in guarantees for subsidiaries, with total guarantee balance reaching 25.8 billion yuan; it also released 2.1514 billion yuan in guarantees.九州通披露2024年1月新增对子公司担保28.5亿元，担保余额为258亿元；同时解除担保21.514亿元。
2024-04-15Jointown provided guarantees totaling 4.047 billion yuan for 43 subsidiaries in March 2024, and released guarantees of 3.805 billion yuan; outstanding guarantee balance reached 24.472 billion yuan as of March 31, 2024.九州通2024年3月为43家控股子公司提供担保合计40.47亿元，解除担保合计38.05亿元；截至3月31日担保余额244.72亿元。
2025-01-17Jointown disclosed that in December 2024 it provided new guarantees of CNY 2.761 billion for 36 subsidiaries, with total outstanding guarantees reaching CNY 27.992 billion.九州通披露2024年12月为36家子公司新增担保27.61亿元，实际担保余额达279.92亿元。
2025-03-16Jointown provided new guarantees totaling 2.2671 billion yuan for 35 subsidiaries in February 2025, and released guarantees of 1.4794 billion yuan; total guarantee balance stood at 28.413 billion yuan.九州通2025年2月为35家子公司新增担保22.671亿元，解除担保14.794亿元，担保余额284.13亿元。
2025-05-16April 2025 guarantee update: new guarantees 4.155 billion yuan, released guarantees 3.015 billion yuan; outstanding guarantee balance 27.724 billion yuan (82.53% of net assets); internal quota adjustment among subsidiaries completed.2025年4月担保进展：新增担保41.55亿元，解除担保30.15亿元；担保余额277.24亿元（占净资产82.53%）；完成子公司授信额度内部调剂。
2025-06-18In May 2025, added 1.474 billion yuan in guarantees for 27 subsidiaries, including Shanghai Jiuzhoutong Pharmaceutical and Guangdong Jiuzhoutong Pharmaceutical. As of 2025-05-31, outstanding guarantee balance was 27.864 billion yuan.2025年5月新增为27家子公司提供担保金额合计14.74亿元，主要对象包括上海九州通医药、广东九州通医药等。截至2025年5月31日，实际担保余额为278.64亿元。
2025-07-17Jointown provided a total of 2.3515 billion yuan in guarantees for 36 subsidiaries (including Xiamen Jointown, Henan Jointown) in June 2025; as of June 30, total outstanding guarantees reached 28.512 billion yuan, 84.88% of 2024 net assets.九州通2025年6月为厦门九州通、河南九州通等36家子公司合计提供23.515亿元担保；截至6月30日，对外担保余额达285.12亿元，占2024年末净资产的84.88%。
2025-08-13Jointown announced that as of July 31, 2025, the balance of guarantees provided for subsidiaries reached 281.17 billion RMB, accounting for 103.21% of audited net assets.九州通公告截至2025年7月31日，为子公司提供的担保余额合计281.17亿元，占经审计净资产的103.21%。
2025-08-14Jointown added 20.7 billion RMB in new guarantees for 37 subsidiaries in July 2025, while releasing 24.65 billion RMB in guarantees.2025年7月，九州通为37家子公司新增担保额度207亿元，同期解除担保金额246.5亿元。
2025-10-22Provided new guarantees totaling RMB 3.45B to 51 subsidiaries in September 2025. As of Sep 30, 2025, actual guarantee balance was RMB 28.96B, accounting for 106.29% of audited net assets.2025年9月为51家子公司新增担保金额34.54亿元。截至9月30日，实际担保余额289.57亿元，占最近一期经审计净资产的106.29%。
2025-12-13In November 2025, Jointown added 2.3247 billion yuan in guarantees for subsidiaries and released 2.4938 billion yuan in guarantees; total outstanding guarantees stood at 28.348 billion yuan as of November 30.2025年11月，九州通新增子公司担保23.25亿元，解除担保24.94亿元；截至11月30日实际担保余额283.48亿元。
Controlling shareholder share pledges & releases控股股东股份质押与解押
38 · 2024-01-18 → 2026-06-23
▾
Controlling shareholder Chuchang Investment and concert parties engage in repeated pledge and release activities.控股股东楚昌投资及其一致行动人反复进行质押和解押操作。
2024-01-18Controlling shareholder Chuchang Investment and Zhongshan Guangyin pledged a total of 29.09 million shares (0.75% of total equity) to Hankou Bank and Hubei Financing Guarantee Group.控股股东楚昌投资和中山广银向汉口银行和湖北省融资担保集团合计质押2909万股（占总股本0.75%）。
2024-03-12Controlling shareholder Chuchang Investment prematurely released and re-pledged shares; after completion, total pledged shares of controlling shareholder and its concert parties reached 49.06% of their holdings, or 23.32% of total shares.控股股东楚昌投资提前解除质押并重新质押股份；完成后，控股股东及其一致行动人累计质押股份占其持股49.06%，占总股本23.32%。
2024-03-29Shareholders Shanghai Hongkang and Zhongshan Guangyin pledged and released pledges on shares; after completion, controlling shareholder and its concert parties' total pledged shares reached 50.97% of their holdings, or 24.19% of total shares.股东上海弘康与中山广银进行股份质押及解除质押；完成后，控股股东及其一致行动人累计质押股份占其持股50.97%，占总股本24.19%。
2024-04-03Shareholder Shanghai Hongkang completed early release of pledge on 83.44 million shares (2.13% of total share capital), reducing its pledged shares to 50.58% of its holdings.股东上海弘康提前解除质押8344万股（占总股本2.13%），其质押股份占其持股比例降至50.58%。
2024-04-19Controlling shareholder Chuchang Investment's exchangeable bond holders exercised conversion rights from March 28, 2023 to April 17, 2024, converting 44.2108 million shares, reducing its shareholding by 1.13%; Chuchang plans to release 81 million shares from guarantee trust.控股股东楚昌投资的可交换债券持有人于2023年3月28日至2024年4月17日期间行使换股权利，累计换股4421.08万股，持股比例被动下降1.13%；楚昌拟解除8100万股的担保及信托登记。
2024-04-23Controlling shareholder Chuchang Investment pledged 8.93 million shares (0.23% of total share capital) to Hankou Bank Hanyang Sub-branch.控股股东楚昌投资向汉口银行汉阳支行质押893万股（占总股本0.23%）。
2024-05-17Controlling shareholder Chuchang Investment and its concert parties pledged 927.16 million shares, representing 50.52% of their holdings and 23.72% of total shares.控股股东楚昌投资及其一致行动人已质押股份9.27亿股，占其所持股份50.52%，占总股本23.72%。
2024-05-18Shareholder Shanghai Hongkang Industrial Investment pledged 56 million shares (1.43% of total) to Ping An Bank Wuhan Branch.股东上海弘康实业投资有限公司向平安银行武汉分行质押5600万股（占总股本1.43%）。
2024-06-19Jointown's controlling shareholder Chuchang Investment and its concert parties completed early release of 51.471 million shares pledge and new pledge of 58 million shares by Shanghai Hongkang, with total pledged shares at 50.80% of their holdings.九州通控股股东楚昌投资及其一致行动人提前解除5147.1万股质押，上海弘康新增质押5800万股，质押股份占其持股50.80%。
2024-08-13Controlling shareholder Chuchang Investment and its concert parties pledged total 1.234 billion shares (52.13% of their holdings, 24.47% of total shares) as of August 13, 2024.截至2024年8月13日，控股股东楚昌投资及其一致行动人累计质押股份12.34亿股，占其所持股份52.13%，占总股本24.47%。
2024-08-14Controlling shareholder Chuchang Investment completed share pledge and trust registration for exchangeable corporate bond '22 Chu EB03' on August 14, 2024.控股股东楚昌投资于2024年8月14日办理完成可交换公司债券'22楚EB03'的股份担保及信托登记手续。
2024-08-23Controlling shareholder Chuchang Investment pledged additional 22 million shares (0.44% of total) to Fubon Bank Wuhan Branch on August 23, 2024; total pledged shares reached 1.256 billion (53.06% of their holdings, 24.91% of total).控股股东楚昌投资于2024年8月23日向富邦华一银行武汉分行追加质押2200万股（占总股本0.44%）；累计质押股份达12.56亿股（占其所持53.06%，占总股本24.91%）。
2024-10-09Controlling shareholder Chuchang Investment prematurely released 40.8156 million shares from pledge (7.72% of its holdings) and pledged 49.2 million shares (9.31% of its holdings); after the transaction, total pledged shares by the controlling shareholder and its concert parties stood at 1.264 billion shares (53.58% of their holdings, 25.08% of total equity).控股股东楚昌投资提前解除质押4,081.56万股（占其持股7.72%），并质押4,920万股（占其持股9.31%）；完成后控股股东及其一致行动人累计质押12.64亿股（占其持股53.58%，占总股本25.08%）。
2024-10-21Shareholder Shanghai Hongkang prematurely released 73.53 million shares from pledge (6.76% of its holdings) and pledged 73 million shares (6.71% of its holdings); after the transaction, cumulative pledged shares by the controlling shareholder and its concert parties were 1.264 billion shares (53.95% of their holdings, 25.07% of total equity).股东上海弘康提前解除质押7,353万股（占其持股6.76%），并质押7,300万股（占其持股6.71%）；完成后控股股东及其一致行动人累计质押12.64亿股（占其持股53.95%，占总股本25.07%）。
2024-11-08Controlling shareholder Chuchang Investment and its concert parties pledge 1.2608 billion shares (53.91% of their holdings, 25% of total shares).控股股东楚昌投资及其一致行动人质押股份12.608亿股（占其持股53.91%，占总股本25%）。
2024-12-25Jointown's controlling shareholder Chuchang Investment and its concert party Shanghai Hongkang completed partial share pledge and release; after the changes, total pledged shares reached 1.2898 billion shares (55.37% of their holdings, 25.58% of total equity).九州通控股股东楚昌投资及其一致行动人上海弘康完成部分股份解除质押及质押，变动后累计质押股份12.898亿股（占其所持股份55.37%，占总股本25.58%）。
2024-12-31Jointown's controlling shareholder Chuchang Investment plans to pledge 16 million shares, and Shanghai Hongkang plans to release and re-pledge shares; after completion, total pledged shares will be 1.3058 billion shares (56.06% of their holdings, 25.90% of total equity).九州通控股股东楚昌投资拟质押1600万股，上海弘康拟解除质押及再质押；完成后累计质押股份13.058亿股（占其所持股份56.06%，占总股本25.90%）。
2025-02-18Joincare disclosed that shareholder Shanghai Hongkang completed the release of 58.02 million shares (1.15% of total shares) from pledge and plans to pledge 31 million shares (0.61% of total shares) to Hankou Bank Hanyang Sub-branch.九州通披露股东上海弘康完成解除质押5802万股（占总股本1.15%），并拟将3100万股（占总股本0.61%）质押给汉口银行汉阳支行。
2025-02-18Joincare shareholder Beijing Dianjin Investment pledged 37 million shares (0.73% of total shares) for loans; shareholder Shanghai Hongkang pledged 31 million shares (0.61% of total shares) for loans, both to Hankou Bank Hanyang Sub-branch.九州通股东北京点金投资质押3700万股（占总股本0.73%），上海弘康质押3100万股（占总股本0.61%），均用于质押贷款，质权人为汉口银行汉阳支行。
2025-03-25Jointown's controlling shareholder Chuchang Investment and its concert parties prematurely released pledges on 78.432 million, 49.02 million, and 0.9 million shares, and newly pledged 105.98 million and 49.02 million shares; total pledged shares reached 1.349 billion shares (57.92% of their holdings).九州通控股股东楚昌投资及其一致行动人提前解除质押7843.2万股、4902万股和90万股，并新质押1.0598亿股和4902万股；累计质押13.49亿股（占其持股57.92%）。
2025-03-29Controlling shareholder Chuchang Investment plans to release 33.5 million shares from guarantee and trust accounts for three exchangeable bonds (22 Chu EB01/02/03), transferring them back to its securities account.控股股东楚昌投资拟将三只可交换债券（22楚EB01/02/03）担保及信托专户中的3350万股解除担保并转回其证券账户。
2025-04-29Jointown's shareholder Zhongshan Guangyin Investment Co., Ltd. pledged 5.9211 million shares (0.12% of total) to Hubei Financing Guarantee Group.九州通股东中山广银投资有限公司向湖北省融资担保集团质押592.11万股，占总股本0.12%。
2025-05-13Shareholders Shanghai Hongkang, Zhongshan Guangyin, and Liu Shulin released pledges of 145 million, 26.91 million, and 18.65 million shares respectively; shareholder Liu Zhaonian pledged 23.16 million shares to Hubei Financing Guarantee Group.股东上海弘康、中山广银、刘树林分别解除质押1.45亿股、2691万股、1865万股；股东刘兆年向湖北省融资担保集团质押2316万股。
2025-06-09Shareholder Shanghai Hongkang released pledge on 72.24 million shares (1.43% of total) and pledged 88.01 million shares (1.75% of total) to Ping An Bank Wuhan Branch. After the move, cumulative pledged shares of controlling shareholder Chuchang Investment and its concert parties stood at 51.68% of their holdings, 23.74% of total shares.股东上海弘康解除质押7224万股（占总股本1.43%），同时向平安银行武汉分行质押8801万股（占总股本1.75%）。完成后，控股股东楚昌投资及其一致行动人累计质押股份占其持股的51.68%，占总股本的23.74%。
2025-06-19Shareholder Zhongshan Guangyin released pledge on 51.729 million shares (1.03% of total); shareholder Shanghai Hongkang released pledge on 58 million shares (1.15%) and pledged 64.11 million shares (1.27%) to Hankou Bank Hanyang Branch. After moves, controlling shareholder concert party pledged shares fell to 49.71% of their holdings (22.84% of total).股东中山广银解除质押5172.9万股（占总股本1.03%）；股东上海弘康解除质押5800万股（占总股本1.15%），并向汉口银行汉阳支行质押6411万股（占总股本1.27%）。完成后，控股股东一致行动人累计质押股份降至其持股的49.71%（占总股本22.84%）。
2025-07-25Shareholder Zhongshan Guangyin completed early release of 31.5 million shares (9.39% of its holdings) and pledged 32 million shares (9.54% of its holdings) to Hankou Bank Hanyang Sub-branch; cumulative pledged shares reached 56.42% of its holdings.股东中山广银投资有限公司提前解除质押3150万股（占其所持股份9.39%），并质押3200万股（占其所持股份9.54%）给汉口银行汉阳支行；累计质押股份占其所持股份56.42%。
2025-08-27Jointown's controlling shareholder Chuchang Investment and its concert parties pledged approximately 1.15 billion shares, accounting for 50.14% of their holdings and 22.8% of total share capital.九州通控股股东楚昌投资及其一致行动人累计质押约11.5亿股，占其所持股份的50.14%，占总股本的22.8%。
2025-11-07Controlling shareholder Chuchang Investment prematurely released pledge on 13 million shares; shareholder Zhongshan Guangyin pledged 13.5 million shares to Hankou Bank.控股股东楚昌投资提前解除质押1300万股；股东中山广银质押1350万股给汉口银行。
2025-11-13Shareholder Shanghai Hongkang pledged 166 million shares (3.29% of total) to Hubei Financing Guarantee Group; cumulative pledges by controlling shareholder group reached 54.27% of their holdings.股东上海弘康质押1.66亿股（占总股本3.29%）给湖北省融资担保集团；控股股东及其一致行动人累计质押比例达54.27%。
2025-11-25Controlling shareholder Chuchang Investment prematurely released pledge on 16 million shares; shareholder Zhongshan Guangyin pledged 70 million shares, raising total pledges by the controlling group to 56.63% of their holdings.控股股东楚昌投资提前解除质押1600万股；股东中山广银新增质押7000万股，控股股东及其一致行动人累计质押比例升至56.63%。
2025-12-05Shareholders Shanghai Hongkong and Beijing Dianjin completed early release of pledges on 31 million and 37 million shares respectively, and new pledges of 52.75 million and 37 million shares to Hankou Bank Hanyang Sub-branch.股东上海弘康和北京点金分别提前解除3100万股和3700万股质押，并向汉口银行汉阳支行新质押5275万股和3700万股。
2025-12-16Controlling shareholder Chuchang Investment redeemed and delisted its 2022 non-public exchangeable corporate bond (second tranche), with 23,841,539 shares transferred back from the guarantee trust account to its own securities account.控股股东楚昌投资兑付并摘牌2022年非公开发行可交换公司债券（第二期），2384.15万股从担保专户划转回自有账户。
2025-12-23Controlling shareholder Chuchang Investment redeemed and delisted its 2022 non-public exchangeable corporate bond (third tranche), with 55,550,840 shares to be transferred back from the guarantee trust account.控股股东楚昌投资兑付并摘牌2022年非公开发行可交换公司债券（第三期），5555.08万股将从担保专户划转回自有账户。
2025-12-31Shareholder Shanghai Hongkong prematurely released pledge on 125.6 million shares (11.54% of its holdings) and re-pledged 122.2 million shares to China Minsheng Bank Wuhan Branch; cumulative pledged shares of controlling shareholder Chuchang Investment and its concert parties stood at 57.43% of their holdings.股东上海弘康提前解除1.256亿股质押（占其持股11.54%），并将1.222亿股质押给民生银行武汉分行；控股股东楚昌投资及其一致行动人累计质押占其持股57.43%。
2026-01-21Controlling shareholder Chuchang Investment and its concert party Zhongshan Guangyin partially released and re-pledged shares: Chuchang released 17.98 million shares and Zhongshan Guangyin released 49.02 million shares; Zhongshan Guangyin newly pledged 64.6 million shares to Hankou Bank Hanyang Branch, raising its cumulative pledge ratio to 99.98% of its holdings.控股股东楚昌投资及其一致行动人中山广银部分解除及新增质押股份：楚昌解除1798万股，中山广银解除4902万股；中山广银新增质押6460万股给汉口银行汉阳支行，累计质押比例升至持股的99.98%。
2026-04-28Major shareholders Shanghai Hongkang and Zhongshan Guangyin pledged a combined 190 million shares (3.77% of total) to兴业国际信托有限公司.大股东上海弘康实业投资有限公司和中山广银投资有限公司合计向兴业国际信托质押1.9亿股，占总股本3.77%。
2026-06-10Controlling shareholder Chuchang Investment and its concert party Shanghai Hongkang completed partial share pledge release and new pledge; total pledged shares reached 1.300 billion shares, 56.76% of their holdings, 25.79% of total shares.控股股东楚昌投资及其一致行动人上海弘康完成部分股份解除质押及新质押；累计质押股份13.004亿股，占其持股56.76%，占总股本25.79%。
2026-06-23Controlling shareholder Chuchang Investment and Shanghai Hongkang completed further share pledge adjustments; cumulative pledged shares 931.11 million, 40.64% of their holdings, 18.46% of total shares.控股股东楚昌投资及上海弘康完成进一步股份质押调整；累计质押9.3111亿股，占其持股40.64%，占总股本18.46%。
Industry standards & policy行业标准与政策
6 · 2024-01-22 → 2026-01-23
▾
Comments on policy impact, business scope changes, and regulatory filings.对政策影响的评论、经营范围变更及监管备案。
2024-01-22Jointown completed business scope change registration to add 'pharmaceutical excipient sales' and filed amended articles of association with Hubei market regulator.九州通完成经营范围工商变更，新增“药用辅料销售”并备案修订后的公司章程。
2024-08-29At H1 results briefing, stated 'Five Same Drugs' price comparison policy is net positive for CSO business long-term; short-term impact on high-price, high-volume clinical products.在半年度业绩说明会上表示，'五同药品'比价政策对CSO业务长期利大于弊；短期对临床价格高、销售量大的品种有影响。
2025-05-232024 annual general meeting approved 14 proposals including profit distribution, executive compensation, auditor appointment, and amendment of articles of association to expand business scope; adopted three-year dividend return plan (2025-2027).2024年年度股东会通过14项议案，包括利润分配、高管薪酬、审计机构聘任、修订公司章程增加经营范围；通过未来三年分红回报规划（2025-2027年）。
2025-06-17Completed industrial and commercial registration changes and charter filing, adding business scope of 'Chinese herbal medicine purchasing, primary agricultural product purchasing, and Chinese herbal medicine (excluding prepared slices) sales'.完成工商变更登记及章程备案，新增“中草药收购、初级农产品收购、地产中草药（不含中药饮片）购销”经营范围。
2025-10-27Board approved to expand business scope and amend the Company's Articles of Association; changes require shareholder meeting approval.董事会审议通过增加经营范围及修订《公司章程》的议案，尚需股东大会审议批准。
2026-01-23Completed industrial and commercial registration change and filed revised Articles of Association with Hubei Market Supervision Bureau, adding business scope including loading/unloading, warehousing, catering, training, conference services, management consulting, legal consulting, health consulting, remote health management, and marketing planning.完成工商变更登记及修订后公司章程备案，新增经营范围包括装卸搬运、仓储、餐饮、培训、会议服务、管理咨询、法律咨询、健康咨询、远程健康管理、市场营销策划等。
Financial results & guidance财务业绩与展望
17 · 2024-02-02 → 2026-05-14
▾
Quarterly, semi-annual, and annual financial results, revenue guidance, and dividend announcements.季度、半年度和年度财务业绩、收入指引及分红公告。
2024-02-02Jiuzhou Tong reported 2023 first three quarters revenue of 114.364 billion yuan, up 11.09% YoY; net profit attributable to parent of 1.824 billion yuan, up 4.89% YoY.九州通公布2023年前三季度营业收入1143.64亿元，同比增长11.09%；归母净利润18.24亿元，同比增长4.89%。
2024-04-26Jointown released 2023 annual report: revenue reached 150.14 billion yuan (+6.92% YoY), net profit attributable to shareholders 2.174 billion yuan (+4.27% YoY), and proposed a cash dividend of 2.50 yuan per 10 shares plus a capital reserve increase of 2.9 shares per 10 shares.九州通发布2023年年报：营业收入1501.4亿元（同比+6.92%），归母净利润21.74亿元（同比+4.27%），拟每10股派发现金红利2.50元并以资本公积金每10股转增2.9股。
2024-05-17Announced 2024 guidance: revenue growth ≥10% YoY, non-GAAP net profit growth ≥12% YoY.公布2024年指引：营业收入同比增长不低于10%，扣非归母净利润同比增长不低于12%。
2024-05-172023 full-year revenue reached 150.14 billion yuan (+6.92% YoY), non-GAAP net profit 1.96 billion yuan (+13.06% YoY).2023年全年营业收入达1501.40亿元（同比增长6.92%），扣非归母净利润19.60亿元（同比增长13.06%）。
2024-08-26Released 2024 semi-annual report: revenue 77.171 billion yuan (-2.76% YoY), net profit 1.208 billion yuan (-10.08% YoY); Q2 net profit 670 million yuan (+24.6% QoQ).发布2024年半年报：营业收入771.71亿元（同比-2.76%），归母净利润12.08亿元（同比-10.08%）；第二季度净利润6.70亿元（环比+24.6%）。
2024-10-28Jointown reported Q3 2024 results: revenue 36.258 billion yuan (+3.57% YoY), attributable net profit 489 million yuan (+1.64% YoY); 9M 2024 revenue 113.429 billion yuan (-0.82% YoY), attributable net profit 1.696 billion yuan (-6.99% YoY); excluding seasonal disease effects, 9M revenue +0.70% and net profit +10.16%.九州通发布2024年三季报：第三季度营收362.58亿元（同比+3.57%），归母净利润4.89亿元（同比+1.64%）；前三季度营收1,134.29亿元（同比-0.82%），归母净利润16.96亿元（同比-6.99%）；剔除季节性因素影响，前三季度营收同比+0.70%，归母净利润同比+10.16%。
2024-11-04Q3 2024 revenue 36.258 billion yuan, +3.57% YoY; net profit 489 million yuan, +1.64% YoY.2024年第三季度营收362.58亿元，同比增长3.57%；归母净利润4.89亿元，同比增长1.64%。
2025-04-28Jointown released 2024 annual report: revenue 151.81 billion yuan (+1.11% YoY), net profit 2.507 billion yuan (+15.33% YoY), operating cash flow turned positive to 3.083 billion yuan.九州通发布2024年年报：营业收入1518.10亿元（同比+1.11%），归母净利润25.07亿元（同比+15.33%），经营活动现金流净额转正为30.83亿元。
2025-05-052024 annual results: revenue 151.810 billion yuan, net profit attributable to parent 2.507 billion yuan (+15.33%), non-GAAP net profit 1.814 billion yuan (-7.47%). 2025 Q1 revenue 42.016 billion yuan (+3.82%), net profit 970 million yuan (+80.38%).2024年年报：营收1518.10亿元，归母净利润25.07亿元（+15.33%），扣非归母净利润18.14亿元（-7.47%）。2025年一季度营收420.16亿元（+3.82%），归母净利润9.70亿元（+80.38%）。
2025-06-04Annual revenue exceeded 150 billion yuan for the first time, reaching 151.81 billion yuan in 2024; net profit attributable to parent surged 39.88% to 2.507 billion yuan; Q1 2025 net profit soared 80.38% to 970 million yuan. Franchised pharmacies reached 30,000 stores.2024年全年营收首次突破1500亿元，达1518.1亿元；归母净利润25.07亿元，同比大增39.88%；2025年一季度净利润飙升80.38%至9.70亿元。加盟药店达3万家。
2025-08-26Jointown reported 2025 H1 results: revenue 81.106 billion RMB (+5.1% YoY), net profit 1.446 billion RMB (+19.7% YoY). Pharmaceutical distribution revenue 67.634 billion (+6.04%), pharmaceutical industry revenue 1.593 billion (+10.77%), digital logistics revenue 587 million (+24.66%).九州通发布2025年半年报：营收811.06亿元（+5.1%），归母净利润14.46亿元（+19.7%）。医药分销收入676.34亿元（+6.04%），医药工业收入15.93亿元（+10.77%），数字物流收入5.87亿元（+24.66%）。
2025-09-04Jointown Pharmaceutical Group released 2025 semi-annual results: revenue 81.106 billion yuan, +5.10% YoY; net profit attributable to parent 1.446 billion yuan, +19.70% YoY. Growth driven by pharmaceutical distribution, industrial (+10.77%), and digital logistics (+24.66%). REITs contributed 438 million yuan net profit. Credit rating upgraded to AAA, first private firm in pharmaceutical distribution sector.九州通医药集团发布2025年半年度业绩：营业收入811.06亿元，同比增长5.10%；归母净利润14.46亿元，同比增长19.70%。增长得益于医药分销、医药工业（+10.77%）及数字物流（+24.66%）。REITs贡献净利润4.38亿元。主体信用评级调升至AAA，为医药流通领域首家获此评级的民营企业。
2025-10-27Board approved Q3 2025 report: 9M revenue RMB 119.33B (+5.20% YoY); net profit RMB 1.975B (+16.46% YoY). New business segments: drug distribution promotion +15.26%, pharmaceutical industry +9.93%, digital logistics +24.95%. REITs listing added RMB 438M net profit.董事会审议通过2025年三季报：前三季度营收1193.27亿元（同比+5.20%）；归母净利润19.75亿元（同比+16.46%）。新兴业务：药品总代推广+15.26%，医药工业+9.93%，数字物流+24.95%。REITs上市增加净利润4.38亿元。
2025-11-04Q3 2025 results: revenue 1193.27 billion yuan (+5.20% YoY), net profit 1.975 billion yuan (+16.46% YoY). Emerging businesses: total-agent promotion revenue +15.26%, pharmaceutical industry +9.93%, digital logistics +24.95%. REIT issuance contributed 438 million yuan net profit.2025年三季报：营收1193.27亿元（同比+5.20%），归母净利润19.75亿元（同比+16.46%）。新兴业务：总代推广收入+15.26%，医药工业+9.93%，数字物流+24.95%。REIT发行贡献净利润4.38亿元。
2026-04-27FY2025 revenue reached CNY 161.39 billion (+6.31% YoY), net profit attributable to shareholders was CNY 2.255 billion (-10.07% YoY); proposed cash dividend of CNY 2.00 per 10 shares.2025年营业收入1613.9亿元（同比+6.31%），归母净利润22.55亿元（同比-10.07%）；拟每10股派发现金红利2元。
2026-04-27Q1 2026 revenue reached CNY 44.783 billion (+6.58% YoY), net profit attributable to shareholders was CNY 733 million (-24.41% YoY) due to high base from REIT listing in prior year; core net profit (excl. non-recurring) rose 7.12%.2026年一季度营业收入447.83亿元（同比+6.58%），归母净利润7.33亿元（同比-24.41%，因上年REITs上市高基数）；扣非净利润同比+7.12%。
2026-05-14Held 2025 annual and 2026 Q1 performance and cash dividend briefing. 2025 revenue reached 161.390 billion yuan, up 6.31% YoY; net profit attributable to parent was 2.255 billion yuan, down 10.07% YoY; operating cash flow was 3.441 billion yuan. 2026 Q1 revenue was 44.783 billion yuan, up 6.58% YoY; net profit attributable to parent was 733 million yuan.举行2025年度及2026年第一季度业绩暨现金分红说明会。2025年营业收入1613.90亿元，同比增长6.31%；归母净利润22.55亿元，同比下降10.07%；经营活动现金流净额34.41亿元。2026年一季度营业收入447.83亿元，同比增长6.58%；归母净利润7.33亿元。
Subsidiary & joint venture establishment子公司与合资公司设立
41 · 2024-02-04 → 2026-06-16
▾
Establishment of new wholly-owned or joint venture subsidiaries across medical devices, pharmaceuticals, and technology.在医疗器械、医药和科技领域设立新的全资或合资子公司。
2024-02-04Jiuzhou Tong established Hubei Jiuzhou Tong Zhuocheng Medical Devices Co., Ltd., with registered capital of 10 million yuan, legal representative Liu Lanfang, covering electronic components retail, supply chain management, and medical device internet information services.九州通成立湖北九州通茁成医疗器械有限公司，注册资本1000万元，法定代表人刘兰芳，经营范围包括电子元器件零售、供应链管理、医疗器械互联网信息服务等。
2024-06-28Jointown indirectly established Dazhou Jiuzhou Medical Devices Co., Ltd. with a registered capital of 50 million yuan, engaged in medical device wholesale and related businesses.九州通间接控股设立达州九州通医疗器械有限公司，注册资本5000万元，经营医用口罩批发等业务。
2024-07-11Jointown co-founded Beijing Shuangjiu Chuangmei Medical Technology Co., Ltd. with Beijing Zhijiuzhi Medical Technology Co., Ltd., with registered capital of 10 million yuan, covering pharmaceutical excipient sales and drug retail.九州通与北京智九智医药科技有限公司共同成立北京双九创美医疗科技有限公司，注册资本1000万元，经营范围包括药用辅料销售和药品零售。
2024-07-12Jointown co-founded Hubei Jointown Fukang Pharmaceutical Co., Ltd. with Zhanyoutong Pharmaceutical Technology Hubei Co., Ltd., with registered capital of 1 million yuan, focusing on drug internet services and AI software development.九州通与战友通医药科技湖北有限公司共同成立湖北九州通福康医药有限公司，注册资本100万元，专注于药品互联网服务和人工智能软件开发。
2024-07-23Jointown indirectly wholly owned Guangzhou Jointown International Trade Co., Ltd., with registered capital of 1 million yuan, covering domestic freight forwarding and Class I medical device sales.九州通间接全资持股成立广州九州通国际贸易有限公司，注册资本100万元，经营范围包括国内货物运输代理和一类医疗器械销售。
2024-08-09Indirectly held subsidiary Wuhan Oushun Commerce Co., Ltd. established with registered capital of 1 million yuan, engaged in cosmetics and medical supplies wholesale/retail.间接控股子公司武汉市欧顺商贸有限公司成立，注册资本100万元，经营范围包括化妆品批发零售及医疗用品销售。
2024-08-12Indirectly held subsidiary Jiuzhoutong Huida Medicine (Hubei) Co., Ltd. established on August 12, 2024, with registered capital of 1 million yuan, 95% owned by Jiuzhoutong, engaged in drug wholesale and medical device sales.间接控股子公司九州通惠达医药(湖北)有限公司于2024年8月12日成立，注册资本100万元，九州通持股95%，从事药品批发和医疗器械销售。
2024-09-12Jointown co-founded Hubei Jointown Pinzhong Medical Co., Ltd. with a registered capital of 10 million yuan, covering businesses including new energy vehicle sales and big data services.九州通与湖北润泽盟医药共同出资成立湖北九州通品众医药有限公司，注册资本1000万元，经营范围包括新能源汽车销售和大数据服务。
2024-09-19Jointown established Jointown (Hunan) Medical Technology Co., Ltd. with a registered capital of 30 million yuan, covering AI system integration and mobile terminal device sales.九州通成立九州通（湖南）医疗科技有限公司，注册资本3000万元，经营范围包括人工智能行业应用系统集成和移动终端设备销售。
2024-10-10Jointown (Sichuan) Medical Laboratory Co., Ltd. was established with a registered capital of 30 million yuan, jointly held by Jointown Medical Equipment Group and Chengdu Xuri Tongda Enterprise Management Co., Ltd., engaging in inspection services and medical device wholesale.九州通（四川）医学检验有限公司成立，注册资本3000万元，由九州通医疗器械集团有限公司和成都旭日通达企业管理有限公司共同持股，经营范围包括检验检测服务和医疗器械批发。
2024-10-21Jointown established Hubei Jointown Fukang Pharmaceutical Co., Ltd. with a 100% stake and 1 million yuan registered capital, engaging in pharmaceutical wholesale and internet drug information services.九州通出资100万元成立湖北九州通福康医药有限公司，持股100%，从事批发业和药品互联网信息服务。
2024-11-12Established wholly-owned subsidiary Hubei Jiuzhoutong Pharmaceutical Co., Ltd. with registered capital of 1 million yuan, engaged in wholesale and internet drug information services.出资100万元设立全资子公司湖北九州通医药有限公司，从事批发业和药品互联网信息服务。
2024-11-18Established wholly-owned subsidiary Jiuzhoutong Huida Pharmaceutical (Hubei) Co., Ltd. with registered capital of 1 million yuan, engaged in retail and drug wholesale.出资100万元设立全资子公司九州通惠达医药（湖北）有限公司，从事零售业和药品批发。
2024-11-22Established wholly-owned subsidiary Oushun International Trade (Hainan) Co., Ltd. via Wuhan Ruishichangda Trading, registered capital 1 million yuan, for medical device sales and trade.通过旗下武汉瑞仕昌达商贸有限公司全资设立欧顺国际贸易（海南）有限责任公司，注册资本100万元，从事医疗器械销售和贸易。
2025-02-10Joincare established a wholly-owned subsidiary Joincare Medical Equipment (Hong'an) Co., Ltd. with registered capital of 10 million yuan, covering sales of Class I and II medical devices, protective supplies, daily chemicals, communication equipment, and automobiles.九州通成立全资子公司九州通医疗器械（红安）有限公司，注册资本1000万元，经营范围包括第一、二类医疗器械销售、防护用品批发、日用百货、通讯设备及汽车销售等。
2025-02-12Joincare established a wholly-owned subsidiary Tianjin Joincare Ruichi Health Technology Co., Ltd. with registered capital of 35 million yuan, covering health consulting, IT consulting, and enterprise management services.九州通成立全资子公司天津九州瑞驰健康科技有限公司，注册资本3500万元，经营范围包括健康咨询、信息技术咨询及企业管理等。
2025-02-13Joincare established a subsidiary Jingmen Joincare Medical Equipment Co., Ltd. with registered capital of 15 million yuan, jointly held by Joincare Medical Equipment Group and Zhongxiang Hongjun Kang Technology Co., Ltd., covering Class III medical device operations.九州通成立荆门九州通医疗器械有限公司，注册资本1500万元，由九州通医疗器械集团有限公司和钟祥市宏俊康科技有限公司持股，经营范围包括第三类医疗器械经营。
2025-02-22Joincare established a wholly-owned subsidiary Shanghai Joincare Medical Equipment Co., Ltd. with registered capital of 10 million yuan, covering Class III medical device operations, medical equipment leasing, and computer hardware and software wholesale.九州通成立全资子公司上海九州通医疗器材有限公司，注册资本1000万元，经营范围包括第三类医疗器械经营、医疗设备租赁及计算机软硬件批发等。
2025-03-10Jointown established Shanghai Jointown Jinshan Medical Devices Co., Ltd. with registered capital of 50 million yuan, wholly owned by its subsidiary Jointown Medical Devices Group.九州通新设上海九州通金山医疗器械有限公司，注册资本5000万元，由旗下九州通医疗器械集团全资持股。
2025-03-24Jointown established Shandong Jiuyunhui Commerce Co., Ltd. with registered capital of 3 million yuan, wholly owned by its subsidiary Wuhan Ruishichangda Commerce, covering food sales and supply chain management.九州通成立山东九云晖商贸有限公司，注册资本300万元，由旗下武汉瑞仕昌达商贸全资持股，涉及食品销售和供应链管理。
2025-03-28Jointown established Beijing Jiuzhou Ruifeng Enterprise Management Co., Ltd. with registered capital of 1 million yuan, wholly owned by its subsidiary Beijing Jingfeng Pharmaceutical Group, covering enterprise management and park management services.九州通成立北京九州瑞丰企业管理有限公司，注册资本100万元，由旗下北京京丰制药集团全资持股，涉及企业管理和园区管理服务。
2025-04-24Jointown established Guangdong Jiuzhou Medical Devices Co., Ltd. in Guangzhou, registered capital 10 million yuan, wholly owned by its medical devices subsidiary, covering instrument and appliance sales.九州通在广州成立广东九州通医疗器械有限公司，注册资本1000万元，由九州通医疗器械集团全资持股，经营范围包括仪器仪表销售等。
2025-06-09Established Tibet Jiuzhoutong Suodang Technology Co., Ltd. in Tibet, with registered capital of 4.8 million yuan, jointly held by Tibet Jiuzhoutong Pharmaceutical and Naidong District Suodang Investment. Business scope includes IoT technology services and Chinese herbal medicine sales.在西藏投资成立西藏九州通索当科技有限公司，注册资本480万元，由西藏九州通医药与乃东区索当投资共同持股。经营范围包括物联网技术服务及中草药销售等。
2025-06-16Established Chongqing Jiuzhoutong Herui Medical Technology Co., Ltd., with registered capital of 15 million yuan, jointly held by Jiuzhoutong Medical Equipment Group. Business scope includes Class III medical device operations and medical equipment leasing.成立重庆九州通合瑞医疗科技有限公司，注册资本1500万元，由九州通医疗器械集团等共同持股。经营范围包括第三类医疗器械经营和医疗设备租赁。
2025-06-24Established Jiuzhoutong (Sichuan) Health Development Co., Ltd., with registered capital of 10 million yuan, jointly held by Jiuzhoutong Medical Equipment Group. Business scope includes supply chain management services.成立九州通（四川）健康发展有限公司，注册资本1000万元，由九州通医疗器械集团等共同持股。经营范围包括供应链管理服务。
2025-07-10Jointown established a new subsidiary 'Wuhan Jiangxia Jointown Medical Devices Co., Ltd.' with registered capital of 10 million yuan, wholly owned by Jointown Medical Devices Group, covering Class I/II medical device sales and auto sales.九州通新设子公司'武汉市江夏九州通医疗器械有限公司'，注册资本1000万元，由九州通医疗器械集团有限公司全资持股，经营范围包括一类、二类医疗器械销售及汽车销售。
2025-07-15Jointown established 'Jointown Smart Medical Laboratory (Hubei) Co., Ltd.' with registered capital of 20 million yuan, jointly held by Jointown Medical Devices Group, covering medical services, medical device sales, and medical research.九州通成立'九州通智慧医学检验（湖北）有限公司'，注册资本2000万元，由九州通医疗器械集团有限公司等共同持股，经营范围包括医疗服务、医疗器械销售及医学研究和试验发展。
2025-07-18Jointown established 'Jointown (Guangdong) Health Development Co., Ltd.' with registered capital of 10 million yuan, jointly held by Jointown Medical Devices Group, covering Class I/II medical device sales and software development.九州通成立'九州通（广东）健康发展有限公司'，注册资本1000万元，由九州通医疗器械集团有限公司等共同持股，经营范围包括一类、二类医疗器械销售及软件开发。
2025-07-24Jointown established 'Chengdu Longkang Kangyuan Pharmaceutical Co., Ltd.' with registered capital of 10 million yuan, jointly held by Sichuan Jointown and Chengdu Longke Heyue Industrial Group, covering drug retail, medical devices, and Chinese herb procurement.九州通成立'成都隆科康源医药有限公司'，注册资本1000万元，由四川九州通医药有限公司与成都隆科和悦实业集团有限公司共同持股，经营范围包括药品零售、医疗器械经营及中草药收购。
2025-08-05Jointown established Xiamen Jointown Medical Supply Chain Management Co., Ltd., registered capital 5 million RMB, wholly owned by Fujian Jointown Medical Supply Chain Management Co., Ltd.九州通成立厦门市九州通医疗供应链管理有限公司，注册资本500万元，由福建省九州通医疗供应链管理有限公司全资持股。
2025-08-05Jointown established Jointown Xinkang (Shanghai) Medical Devices Co., Ltd., registered capital 20 million RMB, jointly held by Jointown Medical Devices Group Co., Ltd.九州通成立九州通芯康（上海）医疗器械有限公司，注册资本2000万元，由九州通医疗器械集团有限公司等共同持股。
2025-08-14Jointown invested in Hubei Jointown Health Management Co., Ltd., holding 51% stake, registered capital 10 million RMB, legal representative Yang Jindong.九州通投资湖北九州通健康管理有限公司，持股51%，注册资本1000万元，法定代表人杨进东。
2025-09-09Jointown invested to establish Hubei Jointown Medical Equipment Co., Ltd., with registered capital of 100 million yuan, wholly owned by its subsidiary Jointown Medical Equipment Group. Business scope includes Class I/II medical device sales, daily necessities, and lab analysis instruments.九州通投资成立湖北九州通医疗器械有限公司，注册资本1亿元，由旗下九州通医疗器械集团有限公司全资持股。经营范围包括第一类、第二类医疗器械销售、日用品销售、实验分析仪器销售等。
2025-10-23Established Henan Jointown Medical Equipment Co., Ltd. with registered capital of 10 million yuan, 51% held by Jointown Medical Devices Group.成立河南九州通医疗器材有限公司，注册资本1000万元，九州通医疗器械集团持股51%。
2025-10-30Established Liaoning Jointown Supply Chain Management Co., Ltd. with registered capital of 20 million yuan, 51% held by Jointown Medical Devices Group.成立辽宁九州通供应链管理有限公司，注册资本2000万元，九州通医疗器械集团持股51%。
2025-11-05Established Jiangsu Jointown Subei Medical Devices Co., Ltd. with registered capital of 20 million yuan, jointly held by Jointown Medical Devices Group and Huai'an Guangyu Medical Devices Co., Ltd.成立江苏九州通苏北医疗器械有限公司，注册资本2000万元，由九州通医疗器械集团有限公司与淮安市广誉医疗器械有限公司共同持股。
2025-11-18Established Hubei Jointown Medical Equipment Co., Ltd. with registered capital of 50 million yuan, wholly owned by Jointown Medical Devices Group.成立湖北九州通医疗器材有限公司，注册资本5000万元，由九州通医疗器械集团有限公司全资持股。
2025-11-18Established Jointown Smart Medical Technology (Taizhou) Co., Ltd., wholly owned by Jointown Medical Health Technology Co., Ltd., focusing on health consulting and wearable smart devices.成立九州通智慧医疗科技（台州）有限公司，由九州通医疗健康科技有限公司全资持股，业务涵盖健康咨询、可穿戴智能设备等。
2025-12-10Jointown established 12 new subsidiaries in 2025 covering electronics and auto sales, forming a 'medical + consumer' ecosystem; the latest is Jointown Smart Medical Technology (Xiangyang) Co., Ltd. with registered capital of 10 million yuan.九州通2025年成立12家涉及电子产品及汽车销售的新公司，形成“医疗+消费”生态；最新为九州通智慧医疗科技(襄阳)有限公司，注册资本1000万元。
2026-01-04Established a new subsidiary, Jiuzhoutong Kangmai (Fujian) Medical Devices Co., Ltd., with registered capital of 15 million yuan, fully owned by Fujian Jiuzhoutong Medical Devices, expanding medical device supply chain footprint.新设子公司九州通康脉（福建）医疗器械有限公司，注册资本1500万元，由福建九州通医疗器械全资持股，拓展医疗器械供应链布局。
2026-06-16Jointown's subsidiary Jiangxi Youke Medical Devices Co., Ltd. was registered, a wholly-owned unit of Jiangxi Jointown Medical Devices; in the past month, Jointown set up over 14 new companies, 6 in medical devices.九州通子公司江西优柯医疗器械有限公司注册成立，为江西九州通医疗器械全资子公司；近一月九州通累计新设公司超14家，医疗器械占6席。
IP & patents知识产权与专利
7 · 2024-02-08 → 2026-03-24
▾
Registration of new software copyrights and medical device certificates.新软件著作权及医疗器械注册证的登记。
2024-02-08Jiuzhou Tong registered a new software copyright 'JZT Data Platform (Android Version) V2.0.0'.九州通新注册《JZT资料平台（Android版）V2.0.0》软件著作权。
2025-03-15Jointown registered two new software copyrights: 'Juzhou Lighthouse Software V3.6.6' and 'Juzhou Zhiyaotong Software V6.80.5'.九州通新注册2项软件著作权：《九州灯塔软件V3.6.6》和《九州智药通软件V6.80.5》。
2025-06-04Registered software copyright for 'Smart Decoction Mini Program Software V1.0'. Year to date, 5 software copyrights registered, up 66.67% YoY. R&D spending in 2024 was 147 million yuan, down 25.38% YoY.新注册《智慧煎药小程序软件V1.0》软件著作权。今年以来新注册软件著作权5个，较去年同期增加66.67%。2024年研发投入1.47亿元，同比减少25.38%。
2025-08-24Jointown registered new software copyright 'Jiuzhou Wandian Digital Management Platform V2.0', bringing 2025 total to 14 software copyrights, up 366.67% YoY.九州通新注册《九州万店数字化管理平台V2.0》软件著作权，2025年累计14个，同比增长366.67%。
2025-10-14Registered new software copyright 'JK.com E-commerce Platform System V1.0.0'. Year-to-date, 22 software copyrights registered (+633.33% YoY). H1 2025 R&D spending RMB 66.79M (-0.08% YoY).新注册《JK.com电商平台系统V1.0.0》软件著作权。今年以来新注册软件著作权22个（同比+633.33%）。2025上半年研发投入6679.03万元（同比-0.08%）。
2026-03-15Registered two new software copyrights: 'Jiuxiaodi Platform V1.0' and 'Jiuxiaocai Platform V1.0'.新注册2项软件著作权：《九小递平台V1.0》、《九小菜平台V1.0》。
2026-03-24Subsidiary Wuhan Coniz Medical Technology obtained medical device registration certificate for Transcranial Repetitive Magnetic Stimulator (valid until 2031-03-17), for adjuvant treatment of ischemic cerebrovascular disease and brain injury in patients aged 3+.控股子公司武汉柯尼兹医疗科技获湖北省药监局颁发“经颅重复磁刺激仪”医疗器械注册证（有效期至2031年3月17日），适用于3岁以上缺血性脑血管病及脑损伤性疾病辅助治疗。
Business development & operations业务发展与运营
11 · 2024-02-22 → 2026-05-28
▾
Expansion plans, new business segments, R&D investment, and operational updates.扩张计划、新业务板块、研发投入及运营更新。
2024-02-22Vice Chairman Liu Zhaonian stated at the Yabuli Forum that Jiuzhou Tong's 2023 revenue is expected to exceed 150 billion yuan, and its 2024 service direction is to provide specialized services to grassroots clinics, building a supply system for the 50,000+ new individual clinics added nationwide in 2023.九州通副董事长刘兆年在亚布力论坛表示，2023年营收预计突破1500亿元，2024年服务方向是面向基层诊所提供专项服务，正在建立体系服务2023年全国新增的5万多家个体诊所的药品供应。
2024-05-17Plans to expand regional chain companies to 27 within 1-2 years, covering all provinces.计划未来1-2年内将区域连锁公司扩张至27家，覆盖所有省份。
2024-10-31Jointown's pharmaceutical industrial self-produced and OEM business revenue reached 2.092 billion yuan in the first three quarters of 2024, up 18.42% YoY; Jingfeng Pharmaceutical has over 300 approved drug numbers, with 150+ varieties in production.九州通2024年前三季度西药工业、中药工业自产及OEM业务销售收入20.92亿元，同比增长18.42%；京丰制药现有批准文号300余个，在产品种150余个。
2024-10-31Jointown's R&D investment in the first three quarters of 2024 was 215 million yuan, up 19.05% YoY; 40 digital transformation projects were initiated, with 32 already rolled out; 207 high-end professionals were recruited in the first three quarters.九州通2024年前三季度研发投入2.15亿元，同比增长19.05%；已立项40个数字化转型项目，其中32个已上线推广；前三季度引进高端专业人才207人。
2024-11-21R&D investment in first three quarters of 2024: 215 million yuan, +19.05% YoY; 40 digital transformation projects initiated, 32 launched.2024年前三季度研发投入2.15亿元，同比增长19.05%；已立项数字化转型项目40个，其中32个已上线推广。
2025-02-18Joincare chairman Liu Changyun attended the 2025 private enterprise symposium and stated the company will firmly advance the 'Three New and Two Transformations' strategy (new products, new retail, new healthcare, digitalization, and REITs) to shift from traditional pharmaceutical distribution to digital, platform-based, and internet-based operations.九州通董事长刘长云参加2025年民营企业座谈会，表示将坚定不移推进“三新两化”战略（新产品、新零售、新医疗、数字化和不动产证券化），推动公司从传统医药分销向数字化、平台化和互联网化转型。
2025-04-17Jointown chairman Liu Changyun stated at Hubei private economy conference that the company will accelerate transformation, expand new tracks and business models, focusing on the big health industry.九州通董事长刘长云在湖北省民营经济发展大会上表示，公司将加速转型升级，拓展新赛道、新业态、新模式，聚焦大健康行业。
2025-07-15Jointown Chairman Liu Changyun, as a private entrepreneur representative, spoke at a State Council Information Office press conference on 'Carrying Forward Entrepreneurship', emphasizing serving grassroots medical needs and digital transformation.九州通董事长刘长云作为民营企业家代表在国新办'弘扬企业家精神'中外记者见面会上发言，强调服务基层医疗需求和数字化转型。
2025-10-29Founder Liu Baolin stated in an interview that Jiuzhou Tong increased investment in Hubei in 2025, including acquiring a company, strengthening logistics center construction, and focusing on digital upgrades. TCM business expected to exceed RMB 6B this year.创始人刘宝林受访表示，2025年集团加大在湖北投资布局，包括收购一家公司、加强物流中心建设、重点投入数字化升级。中药业务今年预计突破60亿元。
2026-04-10Medical device unit co-hosted an instant retail summit with Taobao Flash Buy and 1688, launching the 'Mashang Jiusong' health flagship store for non-pharma health products instant delivery.医疗器械集团联合淘宝闪购和1688举办即时零售峰会，发布‘玛上就送’医疗健康旗舰店，提供非药大健康产品即时送达服务。
2026-05-28Won the bid for Jingmen Maternal and Child Health Hospital's color Doppler ultrasound diagnostic instrument procurement project, with a winning bid amount of 2.266 million yuan.中标荆门市妇幼保健院彩色多普勒超声诊断仪采购项目，中标金额226.60万元。
Other developments其他动态
5 · 2024-03-04 → 2026-06-01
▾
Assorted one-off developments.零散的一次性动态。
2024-03-04Vice President Yang Jumei of Jointown Pharmaceutical Group visited KPC Pharmaceuticals (600422) to discuss deepening cooperation in drug distribution and market expansion.九州通医药集团副总裁杨菊美到访昆药集团（600422），双方就深化药品流通与市场拓展合作进行交流。
2024-05-31Implemented 2023 annual dividend: cash dividend of 0.25 yuan per share (total 977 million yuan) plus bonus share of 0.29 per share, record date June 6.实施2023年度权益分派：每股派发现金红利0.25元（合计9.77亿元），每10股转增2.9股，股权登记日为6月6日。
2024-08-26H1 2024 net cash flow -881 million yuan (+0.51% YoY); operating cash flow -3.201 billion yuan; attributed to lower accounts receivable collection in mid-year.2024年上半年净现金流-8.81亿元（同比+0.51%）；经营性现金流-32.01亿元，主要因年中应收账款清收力度较小。
2025-06-10Announced 2024 annual cash dividend plan: A-share cash dividend of 0.20 yuan per share (tax included), with record date on 2025-06-16 and ex-dividend date on 2025-06-17.公告2024年年度权益分派方案：A股每股现金红利0.20元（含税），股权登记日为2025年6月16日，除权（息）日和现金红利发放日为2025年6月17日。
2026-06-01Jointown announced 2025 annual cash dividend: RMB 2.00 per 10 shares (tax incl.), total distribution RMB 997.29 million, 44.23% of net profit; record date June 5, ex-dividend June 8.九州通公布2025年度现金分红：每10股派2.00元（含税），合计分配9.9729亿元，占净利润44.23%；股权登记日6月5日，除权除息日6月8日。
Debt & capital market issuances债务与资本市场发行
12 · 2024-03-13 → 2026-04-03
▾
Issuance of ABN, preferred shares, ABCP, sci-tech innovation bonds with record low coupon rates.发行ABN、优先股、ABCP、科创债，票面利率创纪录新低。
2024-03-13Jointown completed issuance of 2024 first tranche asset-backed notes (ABN) with total amount of 1 billion yuan; shareholder Chuchang Investment subscribed 6 million yuan of priority B and 50 million yuan of subordinated tranches, constituting a related-party transaction.九州通完成2024年度第一期资产支持票据发行，总额10亿元；股东楚昌投资认购优先B级600万元及次级5000万元，构成关联交易。
2024-07-07Jointown received approval from the China Securities Regulatory Commission to issue up to 17.9 million preferred shares, raising up to 1.79 billion yuan to optimize capital structure.九州通获得中国证监会批复，同意向特定对象发行不超过1790万股优先股，募集资金不超过17.9亿元，以优化资本结构。
2024-07-19Jointown issued the first private enterprise asset-backed debt financing instrument in Hubei province, with a scale of 500 million yuan and a coupon rate of 2.25%, a record low for Jointown's bonds.九州通发行湖北省首单民营企业资产担保债务融资工具，规模5亿元，票面利率2.25%，创九州通债券票面利率新低。
2024-07-19Jointown completed the issuance of the 2024 second tranche of asset-backed notes totaling 1 billion yuan, with a record low coupon rate for private enterprises in China for the same tenor and type.九州通完成2024年度第二期资产支持票据发行，总额10亿元，票面利率创中国民企同期限同品种新低。
2024-09-18Jointown received CSRC approval to issue 17.9 million preferred shares, raising 1.79 billion yuan at a face value of 100 yuan and a dividend rate of 5.00%, to be listed on SSE on Sep 24, 2024.九州通获中国证监会批复，向特定对象发行1790万股优先股，募集资金17.90亿元，面值100元，票面股息率5.00%，将于2024年9月24日在上交所挂牌。
2024-10-15Jointown received a 2-billion-yuan Asset-Backed Commercial Paper (ABCP) registration acceptance notice from the National Association of Financial Market Institutional Investors (NAFMII), valid for 2 years, with Zhejiang Bank as lead underwriter.九州通收到中国银行间市场交易商协会签发的20亿元资产支持商业票据（ABCP）《接受注册通知书》，有效期2年，由浙商银行主承销。
2025-08-06Jointown implemented 2025 preferred stock dividend: 5.00% coupon rate, 5.00 RMB per share (tax included), total 89.5 million RMB, on 17.9 million preferred shares (code 360047).九州通实施2025年优先股股息派发：票面利率5.00%，每股5.00元（含税），总计8950万元，涉及1790万股优先股（代码360047）。
2025-11-21Issued the 2025 first tranche of asset-backed notes (ABN) totaling 1 billion yuan, with a priority tranche of 950 million yuan (coupon 2.50%) and a subordinated tranche of 50 million yuan subscribed by controlling shareholder Chuchang Investment.完成2025年度第一期资产支持票据发行，总额10亿元，优先级9.5亿元（票面利率2.50%），次级0.5亿元由控股股东楚昌投资认购。
2025-12-19Jointown received NDRC registration acceptance for 3 billion yuan ultra-short-term commercial paper and 3 billion yuan medium-term notes, valid for 2 years, with joint lead underwriters including China Merchants Bank and China Everbright Bank.九州通获交易商协会接受注册通知书，超短期融资券注册金额30亿元、中期票据注册金额30亿元，有效期2年，联席主承销商包括招商银行、光大银行等。
2026-01-20Issued 2026 first-phase science and technology innovation bond (SCP) in the interbank bond market: amount 300 million yuan, tenor 180 days, coupon rate 1.70%, proceeds received on January 21; this is the first credit bond after AAA rating and the first sci-tech innovation bond by a Hubei private enterprise, with subscription multiple of 3.1 times.在银行间债券市场发行2026年度第一期科技创新债券（超短融），金额3亿元，期限180天，票面利率1.70%，募集资金1月21日到账；为获AAA评级后首单信用债及湖北省民企首单科创债，认购倍数3.1倍。
2026-03-10Issued 2026 second tranche of technology innovation bonds (3-year, RMB 300 million, coupon 1.8%), the lowest coupon rate among private enterprise bonds in China, with a subscription ratio of 3.8 times.发行2026年度第二期科技创新债券（3年期，3亿元，票面利率1.8%），创中国民营企业债券最低发行利率，全场认购倍数3.8倍。
2026-04-03Received NAFMII registration to issue up to CNY 4 billion in asset-backed notes, valid for 2 years, with SPD Bank and Hankou Bank as joint lead underwriters.获得中国银行间市场交易商协会注册批准，发行总额不超过40亿元的资产支持票据，有效期2年，由浦发银行和汉口银行担任联席主承销商。
Executive & governance高管与公司治理
6 · 2024-03-28 → 2026-05-21
▾
Changes in board, supervisors, senior management, and governance policy updates.董事会、监事、高管变动及治理政策更新。
2024-03-28Employee representative supervisor Xiao Ya resigned for personal reasons; Liu Qingxin was elected as the new employee representative supervisor at the职工代表大会 on March 28.职工代表监事肖亚因个人原因辞职；刘庆鑫于3月28日职工代表大会当选新任职工代表监事。
2024-12-03Jointown appointed Liu Yichang as vice chairman; He Wei stepped down as manager.九州通新增刘义常为副董事长，贺威从经理职务退出。
2025-05-24Wu Zhilong elected as employee representative director of the 6th board of directors by the 5th employee congress, effective from May 22, 2025.吴志龙在第五届职工代表大会第一次会议上当选为第六届董事会职工代表董事，自2025年5月22日起任职。
2025-10-27Adopted the 'Management System for Shareholding Changes of Directors and Senior Management' to regulate share transactions and prohibit derivative trading based on company stock.制定《董事和高级管理人员所持本公司股份及其变动的管理制度》，规范股份交易，禁止以公司股票为标的物的衍生品交易。
2026-01-072026 first extraordinary general meeting approved multiple proposals: 2026 comprehensive credit line applications from banks and other institutions, guarantee provision for such credit and other business, 2026 entrusted wealth management plan with temporary idle funds, 2025 related-party transaction report and 2026 forecast, business scope expansion, and revised Articles of Association and director/senior management compensation system.2026年第一次临时股东会审议通过多项议案：2026年度向银行等机构申请综合授信计划、提供担保、使用临时闲置资金委托理财、2025年度关联交易报告及2026年度预计、增加经营范围、修订公司章程及董事高管薪酬制度。
2026-05-212025 annual general meeting of shareholders approved all seven proposals, including 2025 profit distribution plan, re-appointment of Zhongzhuo Huihuan Certified Public Accountants as 2026 auditor, and revision of certain management systems.2025年年度股东会审议通过全部七项议案，包括2025年度利润分配预案、续聘中审众环会计师事务所为2026年审计机构、修订部分管理制度等。
AI & digital transformation initiativesAI与数字化转型举措
12 · 2024-04-07 → 2026-05-14
▾
AI joint lab with Peking University, internal AI assistant 'Smart Jiuge', orthopedic smart platform, and DeepSeek integration drive digitalization.与北大共建AI联合实验室，内部AI助手'智玖哥'，骨科智能平台，接入DeepSeek推动数字化。
2024-04-07Jointown signed a framework agreement with Peking University Wuhan Artificial Intelligence Institute to jointly establish the 'PKU-Wuhan AI-Jointown AI Joint Lab', focusing on digital management, smart supply chain, and AI empowerment for 4 years.九州通与北京大学武汉人工智能研究院签署框架协议，联合成立“北大武汉院-九州通人工智能联合实验室”，聚焦数字化管理、智能供应链和人工智能赋能，合作期限四年。
2024-07-03Jointown launched an internal AI assistant named 'Smart Jiuge' on DingTalk, providing knowledge Q&A for marketing, store operations, and risk control to support digital transformation.九州通在钉钉上推出内部AI助理‘智能九哥’，为市场营销、门店运营、职能风控等提供知识问答，支持数字化转型。
2024-08-01Cooperated with Wuhan Artificial Intelligence Research Institute to form 'Orthopedic Chang'e Smart Service Platform'; signed strategic agreement with Tencent Health for digital management, financial payment, business intelligence, IT R&D, and internet innovation; co-built AI joint lab with Peking University Wuhan AI Research Institute.与武汉人工智能研究院合作形成'骨科嫦娥智慧服务平台'；与腾讯健康签订战略协议，就数字化管理、金融支付、业务智能、IT研发及互联网创新等开展合作；与北京大学武汉人工智能研究院共建人工智能联合实验室。
2024-08-29At H1 results briefing, disclosed 38 digital transformation projects ongoing; 'Medical Supplies Digital Supply Chain Management Platform' and 'TCM Traceability Platform' won 'Digital Transformation Benchmark Cases' awards.在半年度业绩说明会上披露，正在实施38个数字化转型项目；'医疗物资数字化供应链管理平台'和'中药追溯平台'获评'数字化转型标杆案例'。
2024-10-08Jointown established an AI joint laboratory with Peking University Wuhan Artificial Intelligence Research Institute, and developed the 'Orthopedic Chang'e Smart Service Platform' using AI; also signed a strategic cooperation agreement with Tencent Health for digital management and smart services.九州通与北京大学武汉人工智能研究院共建人工智能联合实验室，开发了“骨科嫦娥智慧服务平台”；还与腾讯健康签订战略合作协议，开展数字化管理和智能服务合作。
2025-02-13Joincare announced that its internal office system has integrated DeepSeek large model to improve office efficiency and leverage AI for business data analysis and decision-making.九州通宣布公司内部办公系统已接入DeepSeek大模型，以提升办公效率，并通过AI深度分析挖掘业务数据价值，优化经营决策。
2025-02-18Joincare announced that it has cooperated with Alibaba Cloud and Tencent Cloud on large model applications, including smart knowledge management, prescription assistance, AI health education, supply chain forecasting, and credit risk control.九州通宣布与阿里云、腾讯云在大模型方面合作，应用于智慧知识管理、处方辅助诊断、AI健康教育、供应链预测及授信风控等领域。
2025-03-13Jointown added 'AI concept' due to joint lab with Peking University Wuhan AI Research Institute, launching internal AI assistant 'Smart Jiuge' and 'Orthopedic Chang'e Smart Service Platform'.九州通因与北京大学武汉人工智能研究院成立联合实验室，推出内部AI助手“智能九哥”及“骨科嫦娥智慧服务平台”，新增AI概念。
2025-04-01Jointown and others established a tech company 'Jin Dong Mi Tech (Wuhan) Co., Ltd.' with registered capital of 12 million yuan, covering AI software development and AI public data platform.九州通等共同成立金董秘科技（武汉）有限公司，注册资本1200万元，经营范围涵盖人工智能应用软件开发、AI公共数据平台等。
2025-05-22Established 'Enterprise Expenditure Management Joint Laboratory' with Shengyi Technology to digitalize non-production expense control, focusing on travel management.与胜意科技成立“企业支出管理联合实验室”，聚焦非生产性费用数字化管控，优化差旅管理。
2026-01-28China Academy of Information and Communications Technology (CAICT) completed a special evaluation of Jiuzhoutong's medical health high-quality dataset, confirming outstanding performance in multimodal data fusion, industry scenario adaptation, and technology self-control, providing a replicable paradigm for pharmaceutical industry dataset construction.中国信通院完成对九州通医疗健康高质量数据集的专项测评，确认在多模态数据融合、行业场景适配及技术自主可控方面表现突出，为医药行业数据集建设提供可复制范式。
2026-05-14Announced new 'Four New and Two Transformations' strategy for 2026-2028, succeeding the 'Three New and Two Transformations' strategy (2023-2025). Deployed nine AI agents (purchasing, sales, operations, store, clinic, logistics, code, data, Zhijiuge) across core business scenarios.宣布2026-2028年全新“四新两化”战略，接替2023-2025年“三新两化”战略。部署覆盖核心业务场景的九大智能体（采购、销售、运营、门店、诊所、物流、代码、数据、智九哥）。
Strategic partnerships with pharmaceutical companies与制药企业的战略合作
18 · 2024-04-22 → 2026-05-29
▾
Signed distribution and strategic cooperation agreements with Eisai, Jingxin, Xiangxue, Dong'e Ejiao, Guangzhou Pharma, and others.与卫材、京新、香雪、东阿阿胶、广药等签署分销及战略合作协议。
2024-04-22Jointown signed a strategic cooperation framework agreement with Jingxin Pharmaceutical (002020) to leverage Jingxin's hospital market products and Jointown's out-of-hospital marketing capabilities for mutual growth.九州通与京新药业（002020）签署战略合作框架协议，利用京新的院内市场产品和九州通的院外营销能力实现共赢发展。
2024-06-08Jointown signed a three-year national distribution agreement with Eisai (China) for the product 'Mecobalamin' (Mecobalamin) in retail and hospital channels (excluding centralized procurement), with a contract value exceeding 1.8 billion yuan.九州通与卫材（中国）药业签署三年期全国总代理协议，负责品种'弥可保'在零售及医疗渠道（集采配送除外）的销售，合约标的超18亿元。
2024-06-08Jointown signed a strategic cooperation agreement with Sichuan Kairui Pharmaceutical to jointly develop resources and expand markets in the pharmaceutical field.九州通与四川科瑞德制药签署战略合作协议，共同致力于医药领域资源开发与市场拓展。
2024-06-24Jointown held a 2024 business communication meeting with Xiangxue Pharmaceutical to launch nationwide business cooperation.九州通与香雪制药召开2024年业务沟通会，启动全国业务合作。
2024-07-12Jointown signed a three-year agreement with Eisai to become the national distributor for 'Mecobalamin' (Mecobalamin) in retail and medical channels (excluding centralized procurement distribution).九州通与卫材药业签署三年合约，成为‘弥可保’在零售渠道及医疗渠道（集采配送除外）的全国总代理。
2024-08-29At H1 results briefing, disclosed strategic partnerships with Dongyangguang Pharma, Bayer, AstraZeneca, Novartis, Huahai Pharma, Jiangxi Golden Throat, Kexue (J&J), Eisai, Jingxin Pharma, and medical device suppliers J&J, Abbott, Fresenius, Roche, etc.; signed 3-year national distribution deal with Eisai for 'Mecobalamin' in May 2024.在半年度业绩说明会上披露，与东阳光药、拜耳、阿斯利康、诺华、华海药业、广西金嗓子、科赴（强生）、卫材、京新药业等药企及强生、雅培、费森尤斯、罗氏等器械供应商深度合作；2024年5月与卫材药业就'弥可保'签订三年全国总代理协议。
2024-10-17Jointown and Xiangxue Pharmaceutical (香雪制药) launched the 'Spark Plan' strategic cooperation in Changchun to deepen collaboration in primary healthcare markets.九州通与香雪制药在长春召开“星火计划”战略合作启动会，深化基层医疗市场合作。
2024-11-07Signed strategic cooperation agreement with Dong'e Ejiao (东阿阿胶) at China International Import Expo.在第七届进博会上与东阿阿胶签订战略合作协议。
2024-11-25Held strategic cooperation meeting with Guangzhou Pharmaceutical Group (广药集团) in Wuhan to deepen product collaboration, channel management, and market expansion.与广药集团在武汉召开战略合作对接会，深化品种合作、渠道管控和市场拓展。
2024-12-11Jointown's vice chairman Liu Yichang visited Yunnan Plant Pharmaceutical (Yunzhi Pharmaceutical) to deepen cooperation in pharmaceutical distribution, logistics, and product promotion across 26 provinces.九州通副董事长刘义常到访云南植物药业，双方就深化药品流通、物流配送和产品推广等合作进行交流。
2025-02-21Joincare signed a 2025 strategic cooperation agreement with Dawn Pharmaceutical (Dynasty Pharmaceutical), leveraging Joincare's nationwide distribution network and digital platform to expand coverage of children's health products, including online-offline integration via the 'Yao99' supply chain platform and 'Haoyaoshi' new retail system.九州通与达因药业签署2025战略合作协议，借助九州通全国分销网络和数字化平台，通过“药九九”供应链平台和“好药师”新零售体系，推动儿童健康产品线上线下全覆盖。
2025-08-16Jointown signed a strategic cooperation agreement with Shouxiangu (寿仙谷) on channel construction, supply chain coordination, and market promotion.九州通与寿仙谷签署战略合作协议，在渠道建设、供应链协同及市场推广等方面展开合作。
2025-10-20Launched strategic cooperation with Baiyunshan Chenliji (Guangzhou Pharmaceutical's subsidiary, a time-honored TCM brand) to jointly develop high-quality TCM industry, leveraging Jiuzhou Tong's channel and digital capabilities.与广州白云山陈李济（广药集团旗下中华老字号）启动战略合作，围绕中医药产业高质量发展开展对接，发挥九州通的渠道与数字化优势。
2025-10-27Jointly launched the 'Huasan Jiuzhou Tianyuan Value Alliance' with China Resources Sanjiu to build a 'diagnosis + treatment + health' smart ecosystem in the Hubei OTC market, integrating brand, channel, and terminal resources.与华润三九联合发起“华润三九天元价值联盟”，在湖北OTC市场打造“诊+疗+健康”智慧生态圈，整合品牌、渠道与终端资源。
2025-12-17Jointown held strategic cooperation talks with Foci Pharmaceutical, reaching consensus on business deepening, resource integration, and 2026-2028 sales growth targets.九州通与佛慈制药举行战略合作洽谈，围绕业务深化、资源整合及2026-2028年销售增量目标达成共识。
2026-01-15Signed strategic cooperation agreement with Tianyao Pharmaceutical Health Technology, covering digital supply chain and terminal service innovation, leveraging nationwide distribution network and supply chain capabilities.与津药药业健康科技签署战略合作协议，涵盖数字化供应链和终端服务创新，利用全国分销网络和供应链能力。
2026-03-13Held a business exchange meeting with Guangzhou Pharmaceutical Group (GP Corp) to deepen cooperation in product distribution, base construction, and logistics coordination.与广药集团召开业务交流会，深化产品经销、基地建设、物流协同等战略合作。
2026-05-29Jiuzhoutong Medical Device Group signed a strategic cooperation agreement with Jiangsu Kunchuan Biotechnology Co., Ltd. to collaborate on clinical application and market promotion of methylation technology in tumor early screening, auxiliary diagnosis, and recurrence monitoring.九州通医疗器械集团与江苏鹍远生物科技股份有限公司签署战略合作协议，围绕甲基化技术在肿瘤早筛、辅助诊断及复发监测等领域的临床应用与市场推广展开合作。
Haoyaoshi retail franchise expansion好药师零售加盟扩张
11 · 2024-04-26 → 2026-05-14
▾
Haoyaoshi franchise store count grows from 21,192 to over 34,500, becoming a key growth driver.好药师加盟店数量从21,192家增长至超过34,500家，成为关键增长引擎。
2024-04-26Jointown's retail brand 'Haoyaoshi' achieved full-year sales of 3.48 billion yuan to franchised pharmacies in 2023, up 83.25% YoY, and aims to exceed 25,000 direct-operated and franchised stores by end of 2024.九州通旗下零售品牌“好药师”2023年向加盟药店全年销售规模达34.8亿元，同比增长83.25%，并力争2024年直营和加盟门店总数突破25000家。
2024-05-17Good Pharmacist '10,000-store franchise' plan reached 21,192 stores by Q1 2024; target of 25,000 stores by end of 2024 and 30,000 by 2025.好药师“万店加盟”计划截至2024年一季度末门店数达21192家；目标2024年底突破2.5万家，2025年超3万家。
2024-07-16Jointown's retail brand Haoyaoshi reached 22,780 stores by end of May 2024, including 22,512 franchised stores (98.82%), with franchisees operating independently.九州通零售品牌好药师截至2024年5月底门店数达22780家，其中加盟药店22512家（占比98.82%），加盟商自负盈亏。
2024-08-26H1 2024 traditional Chinese medicine business revenue 2.377 billion yuan; 'Wandian Jiarmeng' (franchise pharmacy) reached 24,387 stores by end of July 2024, with 5,499 new stores added in H1.2024年上半年中药业务收入23.77亿元；'万店加盟'好药师自营及加盟药店截至7月底达24387家，上半年新增5499家。
2024-09-04Jointown's retail brand Haoyao Shi reached 25,663 direct-sale and franchise pharmacies by Aug 31, 2024, ahead of its annual target; sales to franchise pharmacies reached 2.419 billion yuan in H1 2024, up 47.32% YoY.九州通零售品牌好药师直营和加盟药店截至2024年8月31日达25,663家，提前完成年度目标；2024年上半年向好药师加盟药店销售收入24.19亿元，同比增长47.32%。
2024-10-08Jointown's retail brand Haoyao Shi (Good Pharmacist) reached 25,663 direct-operated and franchised stores as of Aug 31, 2024, achieving the 2024 annual target ahead of schedule; year-end target is 30,000 stores.九州通旗下零售品牌好药师直营和加盟药店截至2024年8月31日达到25,663家，提前完成2024年度目标，年底目标为30,000家。
2024-10-31As of end-Q3 2024, Jointown's Haoyao Shi retail stores reached 26,703, ahead of the 2024 target; year-end target remains 30,000 stores.截至2024年三季度末，九州通好药师直营和加盟药店达到26,703家，提前完成2024年度目标，年底目标仍为30,000家。
2024-11-07Retail brand Haoyaoshi (好药师) direct-sale and franchise stores reached 26,703 by end of Q3 2024, hitting annual target early; year-end target 30,000.零售品牌好药师直营和加盟药店截至2024年第三季度末达26,703家，提前完成年度目标；年底目标30,000家。
2025-05-08New retail strategy: 'Wandian Jiarmeng' (10,000-store franchise) stores exceeded 29,000; 2024 franchise sales 5.392 billion yuan (+54.94%), C-end new retail revenue 2.966 billion yuan; target of 33,000 stores by 2025.新零售战略：“万店加盟”门店超2.9万家；2024年加盟店销售53.92亿元（+54.94%），C端新零售收入29.66亿元；预计2025年门店超33,000家。
2025-08-30Jointown ranked 4th in China Pharmaceutical Commercial Association's 2024 wholesale revenue top 100; its Haoyishi pharmacy ranked 9th in retail sales top 100. Haoyishi加盟 stores reached 31,535 by end of June 2025, with sales to加盟 pharmacies of 3.418 billion RMB (+41.3% YoY).九州通在2024年药品批发企业百强中排名第四，好药师在零售企业百强中排名第九。好药师加盟药店达31535家，向加盟药店销售收入34.18亿元（+41.30%）。
2026-05-14As of end of March 2026, Haoyaoishi direct-sale and franchise stores exceeded 34,500, covering 293 prefecture-level cities. New retail (including B2C e-commerce) revenue was 2.879 billion yuan; instant retail revenue in 2025 was 460 million yuan, covering 7,000 stores.截至2026年3月底，好药师直营及加盟门店总数超34,500家，覆盖293个地级市。新零售业务（含B2C电商）销售收入28.79亿元；即时零售2025年销售收入4.60亿元，服务门店7,000家。
CSO / Quanqing Health brand promotion businessCSO/全擎健康品牌推广业务
9 · 2024-04-26 → 2026-03-24
▾
Total agency brand promotion (CSO) revenue grows steadily, rebranded as Quanqing Health, becoming the second profit growth curve.总代理品牌推广（CSO）收入稳步增长，品牌升级为全擎健康，成为第二利润增长曲线。
2024-04-26Jointown's 2023 CSO (total agency brand promotion) business revenue reached 19.584 billion yuan (+46.01% YoY), with gross profit of 2.789 billion yuan (+52.45% YoY), becoming the 'second growth curve' for profit.九州通2023年总代品牌推广业务（CSO）收入达195.84亿元（同比+46.01%），毛利额27.89亿元（同比+52.45%），成为利润增长“第二曲线”。
2024-05-17Total agency brand promotion (CSO) revenue in 2023 reached 19.584 billion yuan (+46.01% YoY), gross profit 2.789 billion yuan (+52.45% YoY).2023年总代品牌推广业务（CSO）收入达195.84亿元（同比增长46.01%），毛利额27.89亿元（同比增长52.45%）。
2024-06-07Jointown established a Brand Marketing Business Unit and released its brand marketing strategy and business model panorama, following the upgrade of its CSO business to the 'Quanqing Health' brand.九州通成立品牌营销事业部，并发布品牌营销业务战略及业务模式全景图，此前CSO业务已升级为'全擎健康'品牌。
2024-08-26H1 2024 CSO (total agency brand promotion) business revenue reached 9.862 billion yuan (+14.18% YoY); pharmaceutical industrial self-produced and OEM revenue 1.438 billion yuan (+21.61% YoY).2024年上半年总代品牌推广业务（CSO）收入达98.62亿元（同比+14.18%）；医药工业自产及OEM业务收入14.38亿元（同比+21.61%）。
2024-10-28Jointown's CSO (total agency brand promotion) business revenue reached 14.119 billion yuan in the first three quarters of 2024, up 18.00% YoY; medical device CSO revenue was 6.535 billion yuan, up 19.12% YoY.九州通2024年前三季度总代品牌推广业务（CSO）销售收入达141.19亿元，同比增长18.00%；医疗器械总代品牌推广业务收入65.35亿元，同比增长19.12%。
2025-05-08New product strategy: total-agent brand promotion (CSO) revenue reached 19.267 billion yuan, gross profit 2.160 billion yuan; cumulative introduction of 2,247 total-agent SKUs, including 52 single-product SKUs with sales over 100 million yuan.新产品战略：总代品牌推广业务（CSO）销售收入达192.67亿元，毛利额21.60亿元；累计引进总代品规2,247个，其中销量过亿单品品规52个。
2025-12-11Jointown's subsidiary Quanqing Health signed an exclusive retail CSO agreement with Hisun Pharma for multiple star products, with first-year cooperation target exceeding 400 million yuan.九州通旗下全擎健康与海正药业签署独家零售CSO协议，负责多款明星产品零售全渠道推广，首年合作标的额超4亿元。
2026-03-12Subsidiary Quanqing Health discussed cooperation with Peking University Medicine on nabumetone capsules for the out-of-hospital market.子公司全擎健康与北大医药就萘丁美酮胶囊院外市场合作进行沟通。
2026-03-24Subsidiary Quanqing Health launched a strategic CSO cooperation project with Haleon (China) to promote brands such as Caltrate, Centrum, Voltaren, Bactroban, and Contac in the broad medical market (BMM).子公司全擎健康与赫力昂（中国）启动战略合作CSO项目，在广阔医学市场推广钙尔奇、善存、扶他林、百多邦、新康泰克等品牌。
Jiuxin Clinic internet medical platform九信诊所互联网医疗平台
7 · 2024-04-26 → 2025-10-28
▾
Jiuxin Clinic membership stores grow from pilot to over 1,377, with AI-assisted diagnosis platform launched.九信诊所会员店从试点增长至超过1,377家，AI辅助诊断平台上线。
2024-04-26Jointown's 'Jiuxin Clinic' internet medical platform is about to go online, aiming to empower grassroots clinics.九州通打造的“九信诊所”互联网医疗平台即将上线，拟为基层诊所赋能。
2024-05-17Launched 'Jiuxin Clinic' brand under new medical strategy, targeting 200 'Jiuxin Clinic' plus alliance clinics in 2024.推出“九信诊所”品牌，新医疗战略目标2024年实现“九信诊所”加联盟200家。
2024-07-18Jointown's new medical strategy 'Jiuxin Clinic' brand developed 297 member stores, providing supply chain, IT systems, and operational services to clinics.九州通新医疗战略‘九信诊所’品牌已发展297家会员店，为诊所提供供应链、IT系统和运营服务。
2024-08-29At H1 results briefing, stated total product SKUs reached 739,700; total B-end clients about 561,200; 'Jiuxin Clinic' membership stores reached 412, targeting 800 for full year.在半年度业绩说明会上表示，经营品种品规共计73.97万个；全渠道B端客户约56.12万家；'九信诊所'会员店达412家，全年目标约800家。
2024-10-31Jointown's 'Jiu Xin Clinic' membership stores reached 466 as of end-Q3 2024, targeting 800 for the full year and 50 benchmark stores.九州通“九信诊所”会员店截至2024年三季度末达到466家，全年目标约800家，并打造50家标杆会员店。
2025-05-08New medical strategy: 'Jiu Yi Clinic' membership reached 1,377 stores; launched 'Jiu Yi Clinic AI-assisted Diagnosis Platform' in cooperation with Tencent Cloud, covering pre-consultation, mid-diagnosis, and post-diagnosis chronic disease management.新医疗战略：“九医诊所”会员店达1,377家；与腾讯云合作开发“九医诊所AI辅助诊断平台”，覆盖诊前、诊中、诊后慢病管理全流程。
2025-10-28Q3 2025 report details: New product strategy – total agency brand promotion revenue RMB 14.73B; pharmaceutical industry self-produced & OEM revenue RMB 2.30B (+9.93% YoY). New retail – Haoyaoshi B2C revenue RMB 817M (+13.00% YoY). New medical – self-developed JiuYi SaaS clinic system deployed in 2,000+ member clinics.三季报详情：新产品战略——总代品牌推广收入147.28亿元；医药工业自产及OEM收入23.00亿元（同比+9.93%）。新零售——好药师B2C收入8.17亿元（同比+13.00%）。新医疗——自研九医SaaS诊所管家系统上线，2000余家诊所会员店使用。
Yao99 B2B e-commerce platform药九九B2B电商平台
4 · 2024-04-26 → 2025-01-26
▾
Yao99 platform self-operated transaction volume grows, with 400,000+ registered users covering 99% of administrative regions.药九九平台自营交易额增长，注册用户超40万，覆盖99%行政区。
2024-04-26Jointown's B2B e-commerce digital distribution business (Yao99 platform) achieved sales of 17.326 billion yuan in 2023.九州通2023年B2B电商数字化分销业务（药九九平台）实现销售173.26亿元。
2024-05-17Yao99 B2B e-commerce platform self-operated transaction volume in 2023 reached 11.241 billion yuan, with 400,000+ registered users and 350,000+ active users covering 99% of administrative regions.2023年药九九B2B电商平台自营交易规模达112.41亿元，注册用户40万+、活跃用户35万+，覆盖全国99%行政区域。
2024-10-28Jointown's B2B platform Yao 99 (药九九) self-operated transaction scale reached 8.11 billion yuan in the first three quarters of 2024; B2C e-commerce total agency sales revenue was 723 million yuan, up 16.43% YoY.九州通药九九B2B电商平台自营交易规模2024年前三季度达81.10亿元；B2C电商总代总销业务收入7.23亿元，同比增长16.43%。
2025-01-26Jointown filed 4 new trademark applications for 'Jiuzhou Lighthouse' and 'Yao99' (药九九), bringing total registered trademarks to 1,244.九州通新提交“九州灯塔”、“药九九”等4件商标注册申请，累计持有注册商标1244件。
B2C e-commerce total agency businessB2C电商总代理业务
3 · 2024-04-26 → 2025-05-08
▾
Haoyaoshi B2C total agency revenue grows, operating flagship stores for over 40 brands and achieving strong Double 11 sales.好药师B2C总代理收入增长，运营40+品牌旗舰店，双11销售强劲。
2024-04-26Jointown's Haoyaoshi B2C e-commerce total agency business achieved annual revenue of 1.215 billion yuan in 2023, up 26.8% YoY, operating official flagship stores for over 40 brands including Novartis, Bayer, and Johnson & Johnson.九州通好药师线上B2C电商总代总销业务2023年实现年销售收入12.15亿元，同比增长26.8%，运营诺华、拜耳、强生等40余个品牌的官方旗舰店。
2024-11-21B2C e-commerce total-distribution revenue in first three quarters of 2024 reached 723 million yuan, +16.43% YoY; Double 11 sales exceeded 216 million yuan, orders +49% YoY.2024年前三季度B2C电商总代总销业务销售收入7.23亿元，同比增长16.43%；双11销售额突破2.16亿元，订单量同比增长49%。
2025-05-08B2C e-commerce total-agent business: Haoyaoshi B2C achieved revenue 980 million yuan, total GMV 1.57 billion yuan; operated over 100 official online flagship stores for brands including Novartis, Novo Nordisk, Omron, Centrum, etc.B2C电商总代总销业务：好药师B2C实现销售收入9.80亿元，全网总销售GMV达15.7亿元；运营诺华、诺和诺德、欧姆龙、善存等百余家品牌官方旗舰店。
Digital logistics & supply chain solutions数字物流与供应链解决方案
7 · 2024-04-26 → 2026-04-03
▾
Logistics technology revenue grows, Bb/BC integrated warehouses deployed nationwide, serving clients like Moutai and Alibaba Health.物流技术收入增长，Bb/BC一体化仓全国部署，服务茅台、阿里健康等客户。
2024-04-26Jointown's digital logistics technology and supply chain solutions business achieved revenue of 849 million yuan in 2023, up 28.45% YoY, serving clients such as Kweichow Moutai, Ali Health, and Dingdang Smart Pharmacy.九州通2023年数字物流技术与供应链解决方案业务实现收入8.49亿元，同比增长28.45%，服务客户包括贵州茅台、阿里健康、叮当智慧药房等。
2024-05-17Logistics Bb/BC integrated warehouse model fully deployed: 6 'BC integrated warehouses' (Hubei, Shanghai, Guangdong, Beijing, Tianjin, Zhejiang) and 24 companies completed Bb integration.物流Bb/BC仓配一体化模式全面部署：已投入运营湖北、上海、广东、北京、天津、浙江6处“BC一体仓”，完成24家公司物流“Bb一体化”改造。
2024-05-17Logistics supply chain solutions revenue in 2023 reached 849 million yuan (+28.45% YoY), gross profit 202 million yuan (+49.44% YoY); serving clients including Moutai and Alibaba Health.2023年物流供应链解决方案收入达8.49亿元（同比增长28.45%），毛利额2.02亿元（同比增长49.44%）；服务客户包括茅台、阿里健康等。
2024-07-09Jointown disclosed its cold chain logistics capabilities: 588 GSP cold storage facilities with 113,600 cubic meters capacity, annual throughput of 166 million boxes, and 99.99% accuracy; partnered with Zhongyuan Xiehe to explore multi-temperature cold chain solutions for clinical samples and cell products.九州通披露冷链物流能力：全国588个GSP冷库，容量11.36万立方米，年吞吐量1.66亿箱，准确率99.99%；与中源协和合作探索临床样本、细胞产品等多温层冷链方案。
2024-10-31Jointown's digital logistics and supply chain solutions revenue reached 734 million yuan in the first three quarters of 2024, up 22.99% YoY; the company has built a nationwide 'Bb/BC integrated' full-channel logistics service system.九州通2024年前三季度数字物流与供应链解决方案收入7.34亿元，同比增长22.99%；公司已搭建全国性“Bb/BC一体化”全渠道物流供应链服务体系。
2025-02-21Joincare's logistics technology subsidiary Hubei Joincare Yunzhi Technology has developed a full-process robot product matrix including latent handling robots, transfer robots, bin handling robots, composite picking robots, truss picking robots, and automatic labeling picking robots, deployed in customer logistics centers.九州通旗下物流科技公司湖北九州云智科技自主研发了覆盖物流中心全流程的机器人产品矩阵，包括潜伏搬运机器人、移载搬运机器人、料箱搬运机器人、复合拣选机器人等，已应用于客户物流中心。
2026-04-03Logistics unit partnered with Neolix to deploy L4 autonomous delivery vehicles for pharmaceutical 'warehouse-to-store' distribution, reducing costs significantly.物流板块与新石器合作，部署L4级无人配送车用于医药‘仓到店’配送，大幅降低配送成本。
Awards & certifications奖项与认证
4 · 2024-04-29 → 2026-05-12
▾
Individual awards, national project selections, and high-tech enterprise certifications.个人奖项、国家级项目入选及高新技术企业认证。
2024-04-29Jointown Vice President Wang Qibing was awarded '2023 China Gold Medal CFO' by the Ministry of Finance's New Finance magazine.九州通副总裁王启兵获评财政部《新理财》杂志社颁发的“2023中国金牌CFO”。
2025-01-11Jointown's '5G-based chronic disease management platform for key populations' project was selected as a National Excellent Project in the MIIT-NHC 5G+ Medical Health pilot.九州通申报的“基于5G的重点人群慢病管理平台建设项目”入选工信部、国家卫健委5G+医疗健康应用试点全国优秀项目。
2026-04-29Subsidiary Jointown Medical Information Technology (Wuhan) passed High-Tech Enterprise certification, entitling it to a 15% reduced CIT rate from 2025 to 2027.控股子公司九州通医疗信息科技（武汉）通过高新技术企业认定，2025年至2027年享受15%企业所得税优惠税率。
2026-05-12Subsidiary Hubei Jiuzhou YunCang Technology Development Co., Ltd. obtained High-Tech Enterprise Certificate, entitling it to a reduced corporate income tax rate of 15% for three years.子公司湖北九州云仓科技发展有限公司获得高新技术企业证书，可连续三年享受按15%的税率缴纳企业所得税的优惠政策。
ESG, CSR & industry recognitionESG、企业社会责任与行业认可
5 · 2024-05-09 → 2025-08-26
▾
Received ESG awards, Red Cross donations, industry rankings, and credit rating upgrade to AAA.获得ESG奖项、红十字会捐赠、行业排名，信用评级升至AAA。
2024-05-09Good Pharmacist donated 5 million yuan to Xiaogan Red Cross and Hubei Red Cross Foundation; company received 'Special Contribution Award' from Red Cross.好药师大药房向孝感市红十字会、湖北省红十字基金会捐赠500万元；公司获中国红十字会“特殊贡献奖”。
2024-05-16Ranked 4th in 2023 China pharmaceutical wholesale enterprise top 20 list; won ESG Development Sharing Award.位列2023年度中国药品流通行业批发企业二十强第4名；获ESG发展共享奖。
2024-05-24Named '2024 ESG Model Enterprise' at the ESG and High-Quality Development Innovation Forum.在ESG与高质量发展创新论坛上获评“2024年度ESG典范企业”。
2025-01-08Jointown donated CNY 1.1316 million worth of medicines (including ibuprofen granules, pediatric Qixingcha granules, etc.) to the Tibet earthquake relief via Hubei Red Cross Foundation.九州通通过湖北省红十字基金会向西藏地震灾区捐赠价值113.16万元的药品（包括布洛芬颗粒、小儿七星茶颗粒等）。
2025-08-26Jointown's main credit rating was upgraded to AAA by China Chengxin International Credit Rating, with a stable outlook, up from AA+.中诚信国际将九州通主体信用等级上调为AAA，评级展望为“稳定”，此前为AA+。
Pharmaceutical warehousing logistics REITs医药仓储物流REITs
33 · 2024-05-17 → 2026-05-14
▾
First pharma warehousing REIT in China listed on SSE, raising 1.158 billion yuan, with Pre-REITs fund also established.中国首单医药仓储REIT在上交所上市，募资11.58亿元，Pre-REITs基金同步设立。
2024-05-17REITs project submitted to NDRC in October 2023, under review; aims to be first pharma warehousing REIT in China.REITs项目于2023年10月向国家发改委提交申报材料，正在审核中；有望成为国内医药仓储物流首单REITs。
2024-06-30Jointown announced plans to launch a Pre-REITs project for pharmaceutical logistics仓储 assets, with initial assets (Shanghai, Hangzhou, Chongqing) totaling 240,000 sqm, net book value of 440 million yuan, and expected fundraising of up to 2 billion yuan; if completed in 2024, it could increase net profit by up to 1.1 billion yuan.九州通公告拟启动医药物流仓储资产Pre-REITs项目，首期入池资产（上海、杭州、重庆）总建面约24万平米，账面净值约4.4亿元，预计募资不超20亿元；若年内完成，预计增加净利润不超11亿元。
2024-07-01Jointown announced the launch of a Pre-REITs project for pharmaceutical logistics warehouse assets, partnering with Gaoh Capital, with an initial asset net book value of about 440 million yuan and expected fundraising up to 2 billion yuan; if completed in 2024, it could increase net profit by up to 1.1 billion yuan.九州通宣布启动医药物流仓储资产Pre-REITs项目，与高和资本合作，首期入池资产账面净值约4.4亿元，预计募集资金不超过20亿元；若2024年内完成，预计增加净利润不超过11亿元。
2024-08-26REITs strategy: built 'public REITs + Pre-REITs' multi-tier real estate equity capital operation platform to revitalize pharmaceutical logistics assets; REITs project submitted to NDRC via Hubei DRC.REITs战略：搭建'公募REITs+Pre-REITs'多层级不动产权益资本运作平台盘活医药物流资产；REITs项目已通过湖北省发改委上报国家发改委。
2024-09-03Jointown's REITs and Pre-REITs projects progressed; it aims to complete the public REITs listing and first Pre-REITs issuance within 2024, with underlying assets being 172,000 sqm of Wuhan warehouse.九州通REITs及Pre-REITs项目进展顺利，力争2024年内完成公募REITs上市及首期Pre-REITs发行，底层资产为武汉17.2万平方米仓储。
2024-09-22Jointown formally submitted the application for its pharmaceutical warehouse logistics infrastructure public REITs to CSRC and SSE on Sep 20, 2024; if completed, it is expected to increase net profit by no more than 700 million yuan.九州通于2024年9月20日正式向中国证监会和上交所提交医药仓储物流基础设施公募REITs申报材料；如发行完成，预计增加净利润不超过7亿元。
2024-09-25Jointown's pharmaceutical warehouse logistics REIT application was officially accepted by CSRC and SSE; the fund is named 'CIFM Jointown Pharmaceutical Warehouse Logistics REIT'.九州通医药仓储物流基础设施公募REITs申报获中国证监会和上交所正式受理，基金名称为“汇添富九州通医药仓储物流REIT”。
2024-10-08Jointown's public REIT application for its Wuhan Dongxihu pharmaceutical logistics asset (172,000 sqm, appraised at 1.17 billion yuan) was submitted to CSRC and SSE on Sep 20, 2024, and formally accepted on Sep 24, 2024; expected to increase net profit by up to 0.7 billion yuan in the issuance year.九州通公募REITs申请（武汉东西湖医药物流资产，17.2万平方米，评估价值11.7亿元）于2024年9月20日提交至中国证监会和上交所，9月24日正式受理；预计发行当年增加净利润不超过7亿元。
2024-10-08Jointown's Pre-REITs project, covering three logistics assets in Shanghai, Hangzhou, and Chongqing (total 240,000 sqm, appraised at up to 1.8 billion yuan), is launched; if issued within the year, it is expected to increase net profit by up to 0.9 billion yuan.九州通Pre-REITs项目（上海、杭州、重庆三处物流资产，总面积24万平方米，评估价值不超过18亿元）已启动；若年内发行，预计增加净利润不超过9亿元。
2024-11-07Pre-REITs fund (Wuhu Tonggao No.1) initial assets: three logistics properties in Shanghai, Hangzhou, Chongqing, total GFA ~240,000 sqm.Pre-REITs基金（芜湖通高壹号基金）首期入池资产：上海、杭州、重庆三处医药物流仓储，总建筑面积约24万平方米。
2024-11-07Public REITs issuance expected to increase net profit by no more than 700 million yuan (audited).公募REITs发行预计增加净利润不超过7亿元（以审计为准）。
2024-11-12Pre-REITs fund to commence filing and fundraising; cornerstone investors and bank loans secured, multiple institutional subscriptions confirmed, first asset closing targeted by end of 2024.Pre-REITs基金启动备案及募集，已落实基石投资人和银行贷款，多家机构认购意向确认，力争2024年内完成首批资产交割。
2024-12-02Jointown's pharmaceutical warehousing logistics infrastructure public REITs application accepted by CSRC and Shanghai Stock Exchange, expected to be the first pharmaceutical industry public REITs in China and the first asset securitization by a private enterprise in Hubei.九州通医药仓储物流基础设施公募REITs申报获中国证监会和上交所受理，有望成为全国医药行业首单公募REITs及湖北省首家实现资产证券化的民营企业。
2024-12-17Jointown plans to transfer 100% equity of its subsidiary Jiuzhou Shourui (holding the Wuhan Dongxihu project, appraised at 1.098 billion yuan) to the public REITs fund managed by China Universal Asset Management, with the REITs targeting to raise 1.111 billion yuan; Jointown will subscribe to 34% of the fund shares for about 378 million yuan.九州通拟将子公司九州首瑞（持有武汉东西湖项目，评估值10.98亿元）100%股权转让给汇添富基金管理的公募REITs，REITs拟募集11.11亿元；九州通将认购34%基金份额约3.78亿元。
2024-12-17Jointown plans to transfer equity of three companies holding Pre-REITs assets (Shanghai Tongda, Hangzhou Zhuoyingtang, Chongqing Shourui) for a total price not exceeding 1.7 billion yuan, with appraised equity value of 1.428 billion yuan.九州通拟转让Pre-REITs项目入池资产相关三家公司（上海通达、杭州卓英堂、重庆首瑞）股权，转让价格总额不超过17亿元，评估值14.28亿元。
2024-12-22Jointown's pharmaceutical warehousing logistics infrastructure public REITs received a no-objection letter from the Shanghai Stock Exchange on December 20, 2024.九州通医药仓储物流基础设施公募REITs于2024年12月20日获得上海证券交易所无异议函。
2024-12-24Jointown's pharmaceutical warehousing logistics infrastructure public REITs received approval from the China Securities Regulatory Commission (CSRC) on December 24, 2024, for the registration of the fund with a 39-year term and 400 million units to be raised.九州通医药仓储物流基础设施公募REITs于2024年12月24日获得中国证监会核准，基金合同期限39年，募集份额总额4亿份。
2025-01-13Jointown's first REIT product, 'CCB Principal Jointown Pharmaceutical REIT', issued an inquiry announcement with an inquiry range of CNY 2.666-2.948/unit and total fund units of 400 million.九州通旗下首只REIT产品“汇添富九州通医药REIT”发布询价公告，询价区间2.666-2.948元/份，基金份额总额4亿份。
2025-01-19CCB Principal Jointown Pharmaceutical REIT set final subscription price at CNY 2.895/unit, targeting total proceeds of CNY 1.158 billion, with subscription period Feb 10-11, 2025.汇添富九州通医药REIT最终认购价格定为2.895元/份，预计募集资金总额11.58亿元，募集期为2025年2月10日-11日。
2025-02-09China's first pharmaceutical warehousing logistics public REIT, the CEF Joincare Pharmaceutical Warehousing Logistics Closed-End Infrastructure Securities Investment Fund (Joincare Pharmaceutical REIT, code 508084), launched on Feb 10 with an issue price of 2.895 yuan per unit and offline subscription multiple of 49.62 times; underlying asset is the Wuhan Dongxihu modern pharmaceutical warehousing logistics project with over 170,000 sqm.国内首单医药仓储物流公募REITs——汇添富九州通医药REIT（508084）10日发行，发行价2.895元/份，网下认购倍数49.62倍；底层资产为武汉东西湖现代医药仓储物流项目，总建筑面积超17万平方米。
2025-02-12Joincare Pharmaceutical REIT completed its offering with total fund shares of 400 million units at 2.895 yuan per unit, raising 1.158 billion yuan; strategic investors subscribed 300 million units (75%), including the original equity holder subscribing 136 million units (34%); offline investors subscribed 70 million units (17.5%) with a 50x subscription multiple; public investors subscribed 30 million units (7.5%) with a record 1192x subscription multiple.汇添富九州通医药REIT完成发售，最终募集基金份额4亿份，发售价格2.895元/份，募集资金总额11.58亿元；战略配售3亿份（75%），其中原始权益人认购1.36亿份（34%）；网下投资者认购0.7亿份（17.5%），有效认购倍数50倍；公众投资者认购0.3亿份（7.5%），有效认购倍数1192倍，创历史新高。
2025-02-19Joincare Pharmaceutical REIT announced that the underlying project company Wuhan Joincare Shourui Supply Chain Service Co., Ltd. completed the ownership registration, legally vesting the fund with the infrastructure project assets.汇添富九州通医药REIT公告，基础设施项目公司武汉九州首瑞供应链服务有限公司已完成权属变更登记，基金合法拥有基础设施项目资产。
2025-02-23Joincare Pharmaceutical REIT announced its listing on the Shanghai Stock Exchange on Feb 27, 2025, with total fund shares of 400 million units, listed shares of 99.73 million units, and a fund term of 39 years; underlying asset is the Wuhan Dongxihu modern pharmaceutical warehousing project with 172,447.79 sqm, appraised at 1.103 billion yuan as of Sep 30, 2024.汇添富九州通医药REIT公告将于2025年2月27日在上交所上市，基金份额4亿份，上市交易份额9973.24万份，基金合同期限39年；底层资产为武汉东西湖现代医药仓储物流项目，建筑面积172,447.79平方米，评估值11.03亿元。
2025-02-27Joincare Pharmaceutical REIT officially listed on the Shanghai Stock Exchange, opening with a 30% daily limit up; total fund shares 400 million units, issue price 2.895 yuan, total raised 1.158 billion yuan; expected to increase Joincare's 2025 net profit by no more than 700 million yuan.汇添富九州通医药REIT正式在上交所上市，开盘涨停30%；基金份额4亿份，发行价2.895元，募集资金11.58亿元；预计增加九州通2025年度净利润不超过7亿元。
2025-02-27Shanghai Stock Exchange approved CITIC Securities to act as a market maker for Joincare Pharmaceutical REIT (code 508084) starting Feb 27, 2025.上交所同意中信证券自2025年2月27日起为九州通R（508084）提供一般做市服务。
2025-03-04Jointown's pharmaceutical warehousing logistics public REIT (Huijiafu Jointown Pharma REIT) listed on Shanghai Stock Exchange, closed up 28.22% on debut, making Jointown a dual-listed company (A-share + REIT).九州通医药仓储物流公募REIT（汇添富九州通医药REIT）在上交所上市，首日收盘涨幅28.22%，使九州通成为A股+REIT双上市企业。
2025-03-17Huijiafu Jointown Pharma REIT completed capital reduction of 603.29 million yuan at project company Wuhan Jiuzhou Shourui Supply Chain Services Co., Ltd., reducing registered capital to 306.11 million yuan.汇添富九州通医药REIT完成项目公司武汉九州首瑞供应链服务有限公司减资6.0329亿元，注册资本降至3.0611亿元。
2025-04-16Jointown completed fundraising for its pharmaceutical warehousing logistics Pre-REITs fund, with first tranche of 826 million yuan fully paid in; the fund will incubate assets for future public REIT expansion.九州通完成医药仓储物流Pre-REITs基金募集，首期资金8.26亿元全部实缴到位，该基金将为公募REITs未来扩募孵化培育优质资产。
2025-05-08Pharmaceutical REIT (Huifu Tianfu Jiuzhoutong Pharmaceutical REIT) listed, the first domestic pharmaceutical warehousing logistics public REIT; completed the first domestic pharmaceutical warehousing logistics Pre-REIT fund, establishing a 'dual listing' platform of equity + assets.汇添富九州通医药REIT上市，为国内首单医药仓储物流公募REITs；完成国内首单医药仓储物流Pre-REITs基金设立，建立“股权+资产双上市”平台。
2025-08-26Jointown completed the IPO of its pharmaceutical warehousing logistics infrastructure public REIT, increasing net profit by 438 million RMB in H1 2025.九州通完成医药仓储物流基础设施公募REITs发行上市，2025年上半年增加净利润4.38亿元。
2025-08-28Huijiafu Jointown Pharmaceutical REIT reported H1 2025 results: revenue 36.02 million RMB, net profit 12.86 million RMB, cash flow distribution rate 1.31% (annualized 3.59%).汇添富九州通医药REIT发布2025年中期报告：收入3602.09万元，净利润1285.92万元，现金流分派率1.31%（年化3.59%）。
2025-12-08The Huijiafu Jiuzhoutong Pharmaceutical Warehousing & Logistics Closed-end Infrastructure Securities Investment Fund announced its first 2025 distribution of 0.9456 yuan per 10 fund units, based on distributable amount of 37.8247 million yuan.汇添富九州通医药仓储物流封闭式基础设施证券投资基金公告2025年度首次分红，每10份基金份额0.9456元，可供分配金额3782.47万元。
2026-05-14REITs strategy: CIFM Jiuzhoutong Pharmaceutical Warehousing Logistics REIT listed on SSE in February 2025, raising 1.158 billion yuan. As of March 31, 2026, closing price up 42.66% from base price. First cash dividend of 37.824 million yuan paid in December 2025. Pre-REITs raised 1.645 billion yuan, with 100% warehouse occupancy rate.REITs战略：汇添富九州通医药仓储物流REIT于2025年2月在上交所上市，募集资金11.58亿元。截至2026年3月31日收盘价较基准价涨42.66%，2025年12月首次现金分红3,782.40万元。Pre-REITs募集资金16.45亿元，仓库出租率100%。
Digital partnerships with Alibaba & Tencent Health与阿里健康、腾讯健康的数字合作
3 · 2024-05-17 → 2024-06-08
▾
Signed agreements with Alibaba Health for drug traceability and with Tencent Health for digital management and smart services.与阿里健康签署药品追溯协议，与腾讯健康合作数字管理和智能服务。
2024-05-17Signed strategic cooperation agreement with Alibaba Health to digitize drug inspection reports using the 'Code to Rest Assured' traceability platform.与阿里健康签署战略合作协议，利用“码上放心”追溯平台推动药检报告单电子化。
2024-05-17Signed strategic cooperation agreement with Tencent Health for digital management, financial payment, business intelligence, IT R&D, and internet innovation.与腾讯健康签订战略合作协议，就数字化管理、金融支付、业务智能、IT研发及“+互联网”创新增长等开展合作。
2024-06-08Jointown signed a strategic cooperation agreement with Alibaba Health to use the 'Code Assurance' traceability platform for electronic drug inspection reports in the full pharmaceutical supply chain, promoting paperless document processing.九州通与阿里健康签署战略合作协议，利用'码上放心'追溯平台开展电子药检报告单在医药流通全链路的落地应用，推动无纸化进程。
Regulatory penalties & legal disputes监管处罚与法律纠纷
12 · 2024-05-17 → 2026-04-17
▾
Subsidiaries fined for substandard drugs, military procurement bans, and multiple sales contract lawsuits.子公司因劣药被罚、被禁止参与军队采购，以及多起销售合同诉讼。
2024-05-17Subsidiary Shandong Jointown fined 126,300 yuan by Shandong Medical Products Administration for selling substandard gastrodin injections.全资子公司山东九州通因销售不符合药品标准的天麻素注射液被山东省药监局没收违法所得12.63万元。
2024-07-17Jointown (Wuhan) Medical Equipment Service Co., Ltd. was suspended from participating in military procurement activities from July 12, 2024, for alleged bid-rigging in a United Imaging PET/CT maintenance project; five other Jointown subsidiaries had prior military procurement bans for similar violations.九州通（武汉）医疗设备服务有限公司因涉嫌在联影PET/CT维保项目中串通投标，自2024年7月12日起被暂停参加全军采购活动；另有5家九州通子公司此前因类似违规被禁止参加军队采购。
2024-08-20Responded to NHSA inquiry on Xinmai Medical's Castor stent pricing, stating Jiuzhoutong only provides distribution logistics for Xinmai Medical, so price adjustment has no impact on its performance.回应国家医保局关于心脉医疗Castor支架价格问询，表示九州通仅为心脉医疗提供配送物流服务，调价对公司业绩无影响。
2024-09-02Jointown's subsidiary Ningxia Jointown was banned from participating in military procurement for 2 years for providing false materials in a medical equipment project of the Rocket Force.九州通子公司宁夏九州通因在火箭军医疗设备项目中提供虚假材料，被禁止2年内参加火箭军范围采购活动。
2025-01-06Two civil lawsuits (sales contract disputes) involving Jointown Pharmaceutical were withdrawn by the plaintiff or dismissed by the court on 2024-12-02.九州通涉及的两起买卖合同纠纷民事诉讼于2024年12月2日被原告撤诉或按撤诉处理。
2025-01-15Jointown faced 5 new court cases on January 15, 2025, including jurisdiction appeals and sales contract disputes with hospitals and pharmaceutical companies.2025年1月15日，九州通新增5件法院诉讼，包括管辖权上诉及与医院、药企的买卖合同纠纷。
2025-01-16Jointown faced 7 new court cases on January 16, 2025, all sales contract disputes with various hospitals and pharmaceutical companies.2025年1月16日，九州通新增7件法院诉讼，均为与多家医院及药企的买卖合同纠纷。
2025-02-12Joincare (600998) faced 7 new court lawsuits on Feb 11, including a copyright infringement lawsuit filed by Beijing Founder Electronics Co., Ltd., and multiple contract dispute lawsuits where Joincare is the plaintiff against various medical institutions.九州通（600998）2月11日新增7件法院诉讼，包括北京北大方正电子有限公司提起的著作权侵权纠纷，以及九州通作为原告的多起买卖合同纠纷。
2025-02-19Joincare (600998) faced 4 new court lawsuits on Feb 19, including jurisdiction appeals from three hospitals and a contract dispute lawsuit filed by Joincare against a community health service center.九州通（600998）2月19日新增4件法院诉讼，包括三家医院的管辖权上诉，以及九州通作为原告的买卖合同纠纷。
2025-09-03A consumer complaint was filed against Jointown subsidiary Shangcheng Jinkang Jointown Pharmaceutical Co., Ltd. on the 12315 platform regarding after-sales service issues for Chinese and Western patent medicines. The case was resolved through mutual settlement.九州通子公司商城金康九州通医药有限公司新增1件消费者投诉，涉及中西成药售后服务问题，经双方自行和解处理。
2026-03-30Subsidiary Chongqing Wanzhou was fined RMB 12,750 (0.5% of procurement amount) and banned from government procurement for one year due to malicious collusion with other suppliers in a hospital bidding project.子公司重庆万州因在云阳县人民医院采购项目中与其他供应商恶意串通，被罚款12750元（采购金额千分之五），列入不良记录名单，一年内禁止参加政府采购活动。
2026-04-17Filed an administrative lawsuit against the China National Intellectual Property Administration at the Beijing Intellectual Property Court, case scheduled for June 9, 2026.作为原告在北京知识产权法院对国家知识产权局提起行政诉讼，案号(2026)京73行初642号，开庭日期为2026年6月9日。
Share buyback program股份回购计划
7 · 2024-06-17 → 2024-12-17
▾
Completed share buyback of 56 million shares for 268 million yuan, for employee stock ownership plan.完成5600万股、2.68亿元股份回购，用于员工持股计划。
2024-06-17Jointown announced a share buyback plan of 150 million to 300 million yuan at a price not exceeding 8.20 yuan per share, for employee stock ownership plan.九州通公告拟以1.5亿元至3亿元回购公司股份，回购价格不超过8.20元/股，用于员工持股计划。
2024-06-18Jointown completed the first tranche of share repurchase, buying back 1.23 million shares for 6.3285 million yuan at prices between 5.11 and 5.18 yuan per share.九州通完成首次回购，以632.85万元回购123万股，成交价5.11-5.18元/股。
2024-07-26Jointown repurchased 51.28 million shares (1.02% of total equity) as of July 25, 2024, spending 246 million yuan, with prices ranging from 4.48 to 5.18 yuan per share.截至2024年7月25日，九州通累计回购5128万股（占总股本1.02%），支付金额2.46亿元，价格区间4.48-5.18元/股。
2024-08-02Completed share buyback of 54.08 million shares (1.07% of total) for 258.84 million yuan, with price range 4.42-5.18 yuan per share, as of July 31, 2024.截至2024年7月31日，累计回购股票5408.05万股（占总股本1.07%），支付总金额2.59亿元，回购价格区间4.42-5.18元/股。
2024-10-08Jointown repurchased 1.39 million shares in September 2024 at a total cost of 6.1806 million yuan; cumulative repurchases reached 55.4705 million shares (1.10% of total equity) as of Sep 30, 2024, with total spending of 265.017 million yuan.九州通2024年9月回购139万股，总金额618.06万元；截至9月30日累计回购5,547.05万股（占总股本1.10%），总支出26,501.70万元。
2024-11-04Cumulative share buyback: 56.0365 million shares (1.11% of total) for ~268 million yuan, price range 4.42-5.49 yuan/share.累计回购股票5603.65万股（占总股本1.11%），支付约2.68亿元，价格区间4.42-5.49元/股。
2024-12-17Jointown completed its share buyback program, repurchasing 56.0365 million shares (1.11% of total equity) at a total cost of 268.0977 million yuan, with prices ranging from 4.42 to 5.49 yuan per share.九州通完成股份回购计划，累计回购5603.65万股（占总股本1.11%），支付总金额2.68亿元，回购价格区间4.42-5.49元/股。
Capital market & financing资本市场与融资
8 · 2024-06-25 → 2025-12-19
▾
Capital increases, bond conversions, credit plans, wealth management, and share repurchase disclosures.增资、债券换股、授信计划、理财及股份回购披露。
2024-06-25Jointown increased its registered capital from approximately 3.909 billion yuan to approximately 5.042 billion yuan.九州通注册资本由约39.09亿元增至约50.42亿元。
2024-10-08Jointown reported cumulative cash dividends and share repurchases of 5.688 billion yuan since listing in 2010 (including 1.419 billion yuan in buybacks), representing 154% of net refinancing; 2023 dividend payout ratio was 44.95%.九州通自2010年上市以来累计现金分红及回购股票共计56.88亿元（含回购14.19亿元），为再融资余额的154%；2023年度分红率44.95%。
2024-12-09Jointown's board approved the 2025 comprehensive credit plan for the company and its subsidiaries from banks and other institutions.九州通董事会审议通过2025年度公司及下属企业申请银行等机构综合授信计划的议案。
2024-12-17Jointown plans to reduce the registered capital of its wholly-owned subsidiary Jiuzhou Medical Investment from 11.5256 billion yuan to 525.6089 million yuan to meet regulatory requirements for establishing a finance company.九州通拟对全资子公司九州通医投减资，注册资本由115.256亿元减少至5.256亿元，以满足设立财务公司的监管要求。
2025-01-09Jointown disclosed that as of Q4 2024, its entrusted wealth management balance was CNY 900 million, with cumulative purchases of CNY 13.3 billion in principal-guaranteed products (expected annualized yield 1.76%-2.70%).九州通披露截至2024年第四季度末，委托理财余额9亿元，累计购买保本型理财产品133亿元（预计年化收益率1.76%-2.70%）。
2025-06-11Controlling shareholder Chuchang Investment's 2022 non-public exchangeable bonds (22 Chu EB01) were exercised by holders from 2024-12-19 to 2025-06-09, converting 14,477,602 shares (0.29% of total). Chuchang's concert party shareholding decreased from 46.23% to 45.94%.控股股东楚昌投资2022年非公开发行的可交换公司债券（22楚EB01）持有人于2024年12月19日至2025年6月9日期间行使换股权利，累计换股14,477,602股（占总股本0.29%）。楚昌投资及其一致行动人持股比例从46.23%被动下降至45.94%。
2025-10-15Q3 2025 entrusted wealth management balance was RMB 0. The company had previously authorized up to RMB 4B for low-risk, principal-guaranteed wealth management products.2025年第三季度末委托理财余额为0元。公司此前授权使用不超过40亿元闲置资金购买保本型理财产品。
2025-12-19Jointown's board of directors reviewed the 2026 comprehensive credit plan for the company and its subsidiaries applying for bank and other institutional credit facilities.九州通董事会审议2026年度公司及下属企业申请银行等机构综合授信计划议案。
Venture capital & industrial funds风险投资与产业基金
8 · 2024-06-26 → 2026-06-18
▾
Established multiple funds including Wuhan Jiuying VC Fund, Beijing Zhihui Jiuzhou VC Fund, focusing on innovative drugs and medtech.设立武汉九盈创投基金、北京智慧九州创投基金等多只基金，聚焦创新药和医疗技术。
2024-06-26Jointown established Hubei Jiuzhou Zhizhi Venture Capital Fund Partnership (limited partnership) with a capital of 200 million yuan, focusing on private equity investment and venture capital management, held by its subsidiaries.九州通旗下企业共同出资设立湖北九州智械创业投资基金合伙企业，出资额2亿元，从事私募股权投资基金管理等业务。
2024-11-08Proposed establishment of Wuhan Jiuying Venture Capital Fund (5 billion yuan total; JZTO commits 245 million yuan as LP, 49% stake) to invest in innovative drugs and high-end generics.拟共同投资设立武汉市九盈创业投资基金（总规模5亿元，九州通作为LP认缴2.45亿元，占比49%），投资创新药和高端仿制药。
2024-12-09Jointown co-founded Wuhan Jiuying Venture Capital Fund Partnership with registered capital of 125 million yuan, focusing on innovative drugs and high-end generics, with Jointown planning to contribute up to 245 million yuan (49% stake).九州通等共同成立武汉市九盈创业投资基金合伙企业，出资额1.25亿元，主要投资创新药、高端仿制药，九州通拟认缴出资2.45亿元（占比不超过49%）。
2025-01-07Jointown's new product strategy investment fund, Wuhan Jiuying Venture Capital Partnership (managed by Beijing Chuchang Private Fund Management, custodian Ping An Bank), completed filing with AMAC (filing code SASJ09).九州通参与设立的武汉市九盈创业投资基金合伙企业（有限合伙）在中国证券投资基金业协会完成备案，备案编码SASJ09。
2025-05-16Wholly-owned subsidiary Beijing Jiuzhoutong Technology Incubator invested 22.99 million yuan (91.96% share) to set up Beijing Zhihui Jiuzhou Venture Capital Partnership (2500 million yuan total) with Beijing Chuchang Private Equity Fund, focusing on drugs, medical devices, medical aesthetics, and anti-aging.全资孙公司北京九州通科技孵化器出资2299万元（占比91.96%），与北京楚昌私募基金共同设立北京智汇九州创业投资合伙企业（总规模2500万元），投资药品、医疗器械、医美、抗衰等领域。
2025-07-04Jointown's wholly-owned grandchild company established an industrial fund 'Beijing Zhihui Jiuzhou Venture Capital Partnership' (SAXH03) with Beijing Chuchang Private Fund Management and Xie Jiafang, focusing on pharma, medical devices, medical aesthetics, and anti-aging; fund completed filing on July 4.九州通全资孙公司联合北京楚昌私募基金管理有限公司及自然人谢家芳设立产业基金'北京智汇九州创业投资合伙企业（有限合伙）'（备案编码SAXH03），聚焦药品、医疗器械、医美及抗衰领域；基金于7月4日完成备案。
2025-11-10The industrial fund 'Wuhan Chuchang Tongda Industrial Investment Fund Partnership' (1000万元 from Beijing Jointown Zhongchuang Tech Incubator, 7.14% stake) completed filing with the Asset Management Association of China (fund code SBHG37).控股孙公司北京九州众创科技孵化器有限公司认缴出资1000万元（占比7.14%）参与的‘武汉市楚昌通达产业投资基金合伙企业’在中国证券投资基金业协会完成备案（备案编码SBHG37）。
2026-06-18Vice Chairman Liu Zhaonian stated at the opening of Jiuzhou Industrial Investment (Guangdong Hengqin) that the new company will focus on industrial investment, medical aesthetics & big health, and industrial funds, leveraging Hengqin policies to explore internationalization.副董事长刘兆年在九州产投（广东横琴）开业仪式上表示，新公司将聚焦产业投资、医美大健康及产业基金，依托横琴政策优势探索国际化路径。
Jingfeng Pharmaceutical product pipeline & approvals京丰制药产品管线与批文
12 · 2024-07-12 → 2026-06-01
▾
Jingfeng obtains multiple API and drug approvals, including furosemide, L-malic acid, rosuvastatin, and passes generic consistency evaluations.京丰获得呋塞米、L-苹果酸、瑞舒伐他汀等多个原料药和制剂批文，通过一致性评价。
2024-07-12Jointown's subsidiary Jingfeng Pharmaceutical has over 150 products, 8 passing generic consistency evaluation, with furosemide injection and atropine sulfate injection winning bids in the 8th and 9th national centralized drug procurement.九州通子公司京丰制药拥有150余个品种，8个通过仿制药一致性评价，呋塞米注射液和硫酸阿托品注射液中标国家第八批和第九批集采。
2024-09-11Jointown's subsidiary Beijing Jingfeng Pharmaceutical (Shandong) received NMPA approval for the API furosemide, a potent diuretic; its injection had hospital sales of 549 million yuan in 2023.九州通子公司北京京丰制药（山东）获国家药监局批准呋塞米原料药上市，该药为强效利尿剂；其注射液2023年医院销售额5.49亿元。
2024-12-20Jointown's subsidiary Beijing Jingfeng Pharmaceutical (Shandong) received NMPA approval for the marketing of API L-malic acid, used in compound electrolyte injection (II) with hospital sales exceeding 150 million yuan in 2022 and 2023.九州通控股子公司北京京丰制药（山东）获国家药监局批准L-苹果酸原料药上市申请，该原料药用于复方电解质注射液（Ⅱ），2022年及2023年医院销售额均突破1.5亿元。
2025-03-18Jointown's subsidiary Beijing Jingfeng Pharmaceutical Group received NMPA approval to become the marketing authorization holder for Rosuvastatin Calcium Tablets (5mg, 10mg), a drug for hypercholesterolemia and dyslipidemia.九州通子公司北京京丰制药集团获国家药监局批准，成为瑞舒伐他汀钙片（5mg、10mg）的上市许可持有人，该药用于治疗高胆固醇血症和血脂异常。
2025-05-08Industrial self-produced and OEM business revenue 3.007 billion yuan (+21.49%); Jingfeng Pharmaceutical obtained supplementary approval for Lactobacillus Granules, and API approvals for Furosemide and L-Malic acid; became MAH for Rosuvastatin Calcium Tablets in March 2025.工业自产及OEM业务收入30.07亿元（+21.49%）；京丰制药获乳酸菌素颗粒剂补充批件，呋塞米、L-苹果酸获原料药上市许可；2025年3月成为瑞舒伐他汀钙片上市许可持有人。
2025-10-16Subsidiary Beijing Jingfeng Pharmaceutical (Shandong) received NMPA approval for Glycopyrrolate API, used for peptic ulcer, chronic gastritis, and COPD. 2024 hospital sales of the injection were RMB 53.58M (+38.29% YoY); 2025 H1 sales were RMB 37.41M (+79.21% YoY); R&D investment approx. RMB 7.23M.子公司北京京丰制药（山东）获国家药监局批准格隆溴铵原料药上市，用于胃/十二指肠溃疡、慢性胃炎及慢阻肺。2024年该注射液医院销售额5358万元（同比+38.29%）；2025上半年销售额3741万元（同比+79.21%）；研发投入约723万元。
2025-12-26Jointown's subsidiary Jingfeng Pharma's affiliate Huiyu Yuanhe received NMPA drug registration certificate for Promethazine Hydrochloride Injection (chemical class 3, two specifications), with R&D investment of about 4.67 million yuan; deemed to have passed generic consistency evaluation.九州通子公司京丰制药下属汇禹远和获国家药监局盐酸异丙嗪注射液药品注册证书（化药3类，两种规格），研发投入约467万元，视同通过仿制药一致性评价。
2026-01-05Subsidiary Huiyu Yuanhe (Hainan) Pharmaceutical received NMPA drug registration certificate for Bupivacaine Hydrochloride Injection, a long-acting amide local anesthetic, with R&D investment of about 4.66 million yuan; the drug is Category 3 chemical registration and deemed to have passed generic consistency evaluation.子公司汇禹远和（海南）药业收到国家药监局盐酸布比卡因注射液药品注册证书，为酰胺类长效局部麻醉药，研发投入约466万元；按化学药品3类获批，视同通过仿制药一致性评价。
2026-04-21Subsidiary Beijing Jingfeng Pharmaceutical received NMPA acceptance notice for its azelastine hydrochloride nasal spray (generic antihistamine) marketing application.控股子公司北京京丰制药收到国家药监局对盐酸氮斯汀鼻喷雾剂（鼻用抗组胺药）上市申请的受理通知书。
2026-05-06Subsidiary Shandong Jingfeng passed GMP compliance inspection for tablet production line (801 workshop), with annual capacity of 3.5 billion tablets for metformin hydrochloride enteric-coated tablets and 1 billion tablets for isosorbide dinitrate tablets.子公司山东京丰片剂生产线（801车间）通过药品GMP符合性检查，年产能盐酸二甲双胍肠溶片35亿片、硝酸异山梨酯片10亿片。
2026-05-26Subsidiary Shandong Jingfeng received Drug Supplement Application Approval Notice for Trihexyphenidyl Hydrochloride Tablets (2mg), passing generic drug consistency evaluation. The drug is a National Medical Insurance Class A product for Parkinson's disease, with hospital sales of 86 million yuan in 2025 and R&D investment of approximately 6.85 million yuan.子公司山东京丰收到盐酸苯海索片（2mg）《药品补充申请批准通知书》，通过仿制药质量和疗效一致性评价。该药为国家医保甲类品种，2025年医院销售额0.86亿元，研发投入约685万元。
2026-06-01Subsidiary Beijing Jingfeng Pharmaceutical (Shandong) received NMPA approval for Azelastine Hydrochloride API; R&D cost ~RMB 2.808 million; validity until May 31, 2031.控股子公司北京京丰制药（山东）获国家药监局批准盐酸氮䓬斯汀原料药上市申请；研发费用约280.80万元；通知书有效期至2031年5月31日。
SHEN211 anti-COVID drug developmentSHEN211抗新冠药物研发
1 · 2024-08-14
▾
Joint venture's oral anti-COVID drug SHEN211 (3CL protease inhibitor) receives clinical trial acceptance.合资公司口服抗新冠药物SHEN211（3CL蛋白酶抑制剂）获临床试验受理。
2024-08-14Joint venture Hubei Jiukangtong Biomedical Co., Ltd.'s oral anti-COVID drug SHEN211 tablet (first non-peptidic 3CL protease inhibitor class 1 innovative drug) received clinical trial registration acceptance from NMPA.合资公司湖北九康通生物医药有限公司研发的口服抗新冠药物SHEN211片（国内首款非拟肽类3CL蛋白酶抑制剂一类创新药）获国家药监局临床试验注册申请受理。
Traditional Chinese medicine (Jiuxin Zhongyao) expansion中药（九信中药）业务扩张
10 · 2024-08-29 → 2026-06-15
▾
TCM segment revenue grows, with GMP-certified decoction plants, standardized planting bases, and brand upgrade projects.中药板块收入增长，拥有GMP认证饮片厂、规范化种植基地，启动品牌重塑。
2024-08-29At H1 results briefing, reported H1 2024 TCM segment revenue 2.377 billion yuan (+5.78% YoY), gross profit 430 million yuan (+7.44% YoY); brand 'Daodi Yao, Jiuxin Zao'.在半年度业绩说明会上报告，2024年上半年中药板块收入23.77亿元（同比+5.78%），毛利额4.30亿元（同比+7.44%）；品牌核心为'道地药，九信造'。
2024-10-31Jointown's traditional Chinese medicine (TCM) segment achieved revenue of 3.58 billion yuan in Q3 2024, up 13.87% YoY; Jiu Xin TCM has 11 GMP-certified modern decoction piece enterprises and over 100 authorized patents.九州通2024年第三季度中药板块实现销售收入35.80亿元，同比增长13.87%；九信中药已建成11家GMP认证现代化饮片企业，拥有授权专利100余项。
2025-05-08Traditional Chinese medicine segment revenue 4.962 billion yuan (+18.14%); Jiuxin Chinese Medicine has 9 core production areas, 21 professional companies, 250,000 mu standardized planting bases, 70+ Dao-di herbs, 14 GAP-certified bases, 15 'Three No One All' brand bases.中药板块收入49.62亿元（+18.14%）；九信中药布局9个核心产区、21家专业公司、25万亩规范化种植基地，14个GAP基地，15个“三无一全”品牌基地。
2025-06-11Established Yulin Jiuxin Jixiang Spice Co., Ltd., with registered capital of 10 million yuan, jointly held by Jiuxin Traditional Chinese Medicine Group (a subsidiary) and Guangxi Mubibi Technology. Business scope includes traditional spice products and Chinese herbal medicine planting.成立玉林九信集祥香料有限公司，注册资本1000万元，由九信中药集团与广西木比白科技共同持股。经营范围包括传统香料制品经营和中草药种植。
2025-06-13Established Chengdu Jiuzhoutong Daodi Traditional Chinese Medicine Co., Ltd., with registered capital of 10 million yuan, jointly held by Jiuxin Traditional Chinese Medicine Group and Sichuan Yongcheng Dingsheng Pharmaceutical. Business scope includes Chinese herbal medicine planting and purchasing.成立成都九信道地中药材有限公司，注册资本1000万元，由九信中药集团与四川勇诚鼎盛药业共同持股。经营范围包括中草药种植和收购。
2025-08-25Jointown's Jiuxin Traditional Chinese Medicine (九信中药) launched a brand重塑 project to upgrade its brand strategy, focusing on star products and expanding into food-medicine homology categories.九州通旗下九信中药启动品牌重塑项目，聚焦明星产品培育，拓展药食同源等大健康消费品类。
2025-08-27Jiuxin Traditional Chinese Medicine (九信中药) signed a strategic cooperation agreement with Pengzhou Economic Development Zone Tianfu Traditional Chinese Medicine City and Chengdu Qilong Traditional Chinese Medicine to build the 'Jiuxin Southwest Traditional Chinese Medicine Whole Industry Chain Innovation Demonstration Base'.九信中药与彭州经开区天府中药城、成都市祺隆中药签署战略合作，共建“九信西南中医药全产业链创新示范基地”。
2025-11-13Juxin Traditional Chinese Medicine's Poria cocos and honeysuckle planting bases passed provincial GAP extension inspections; Tianma and Poria cocos received 'Quality Chinese Medicinal Materials' certification.九信中药旗下茯苓、金银花种植基地通过省级GAP延伸检查，天麻与茯苓获授‘品质中药材’认证。
2026-05-14Traditional Chinese medicine segment revenue in 2025 reached 6.224 billion yuan (including industrial), up 25.43% YoY. Invested in 22 professional Dao-di herb companies, with planting area of 1.2 million mu, 13 GMP-certified decoction piece enterprises, and over 120 smart TCM pharmacies in medical alliances.2025年中药板块整体销售收入62.24亿元（含中药工业），同比增长25.43%。投资建设22家专业道地药材公司，种植面积120万亩，布局13家GMP认证饮片企业，运营120余个医共体智慧中药房。
2026-06-15Jointown, together with Inner Mongolia Federation of Industry and Commerce and Drug Administration, conducted field research in Bayannur, Ordos, and Chifeng on TCM industry cooperation, focusing on standardized planting, deep processing, and digital TCM.九州通与内蒙古自治区工商联、药监局赴巴彦淖尔、鄂尔多斯、赤峰开展中医药产业调研，聚焦道地药材标准化种植、精深加工、数字中医药建设。
Supply chain finance & JD Technology partnership供应链金融与京东科技合作
2 · 2024-09-02 → 2025-10-17
▾
Partnered with JD Technology to provide supply chain finance to downstream distributors, addressing long payment cycles.与京东科技合作，为下游经销商提供供应链金融，解决长账期问题。
2024-09-02Jointown partnered with JD Technology to provide supply chain finance (initial credit line 3 million yuan) to downstream distributors, addressing long payment cycles.九州通携手京东科技，为下游经销商提供供应链金融服务（初始授信额度300万元），应对账期长问题。
2025-10-17CITIC Trust launched the '2025 CITIC Trust Jiuzhou Tong No.1 Service Trust', using Jiuzhou Tong's high-quality accounts receivable to create a supply chain capital recycling platform, supporting digital transformation.中诚信托发起设立“2025年中诚信托九州通1号服务信托”，以九州通优质应收账款资产为核心，打造供应链资金循环平台，支持数字化转型。
Related-party transactions & asset impairment关联交易与资产减值
3 · 2024-10-28 → 2025-05-15
▾
Disclosure of related-party transactions and asset impairment provisions.关联交易披露及资产减值计提。
2024-10-28Jointown recorded asset impairment provisions of approximately 261 million yuan for the first three quarters of 2024, reducing pre-tax profit by the same amount.九州通2024年前三季度计提各项资产减值准备约2.61亿元，导致利润总额减少约2.61亿元。
2024-12-09Jointown disclosed 2024 related-party transactions (actual 14.09 billion yuan in Jan-Oct vs. estimated 26.13 billion yuan for full year) and 2025 estimated related-party transactions of no more than 21.06 billion yuan.九州通披露2024年度关联交易执行情况（1-10月实际发生14.09亿元，全年预计26.13亿元）及2025年度关联交易预计不超过21.06亿元。
2025-05-15China Resources Sanjiu (华润三九) publicly listed 51% equity of Hubei Jiuzhoutong Pharmaceutical Technology for 10.86 million yuan; Jiuzhoutong holds the remaining 49%.华润三九公开挂牌转让湖北九州通医药科技51%股权，转让底价1086万元；九州通持有剩余49%。
Beijing digital health headquarters project北京数字健康总部项目
2 · 2024-12-26 → 2026-01-07
▾
Won bid for land in Daxing Biomedical Base to build digital health headquarters, with total investment of 1.2 billion yuan.竞得大兴生物医药基地地块建设数字健康总部，总投资12亿元。
2024-12-26Jointown's subsidiary Beijing Jiuzhou Pharmaceutical won a 1.86 billion yuan bid for an M1 industrial land parcel (7.9 hectares, 133,500 sqm) in Daxing Biomedical Industry Base, Beijing, to build a digital health headquarters project.九州通子公司北京九州通以约1.86亿元竞得北京大兴生物医药产业基地M1工业用地（7.9公顷，建筑规模13.35万平方米），拟建设数字健康总部基地项目。
2026-01-07Digital Health Headquarters Base project in Beijing broke ground; covers 118 mu, total floor area 256,300 sqm, total investment 1.2 billion yuan, positioned as digital-intelligent pharmaceutical supply chain headquarters and Beijing-Tianjin-Hebei core logistics hub, with storage capacity of 1.5 million items and supporting 20 billion yuan annual medical logistics economic zone.北京数字健康总部基地项目破土动工，占地118亩，总建筑面积25.63万平方米，总投资12亿元，定位为数智医药供应链总部及京津冀核心物流枢纽，具备150万件药械仓储能力，支撑年200亿规模医药物流经济区。
New energy subsidiaries (solar power)新能源子公司（光伏）
3 · 2025-03-21 → 2025-06-30
▾
Established multiple new energy subsidiaries focusing on solar power generation and technology services.设立多家新能源子公司，专注于光伏发电和技术服务。
2025-03-21Jointown indirectly wholly owned Honghu Zhuoyingtang New Energy Co., Ltd. established with registered capital of 1 million yuan, engaging in power generation and solar thermal power sales.九州通间接全资持股的洪湖卓英堂新能源有限公司成立，注册资本100万元，从事发电业务和太阳能热发电销售。
2025-04-29Jointown indirectly wholly owned a new company Luzhou Zhuoyingtang Photovoltaic Power Generation Co., Ltd., registered capital 500,000 yuan, covering solar power technology and energy-saving services.九州通间接全资持股成立泸州卓英堂光伏发电有限公司，注册资本50万元，经营范围包括太阳能发电技术服务、节能管理服务等。
2025-06-30Established Chongqing Jiuzhou Yaoyang New Energy Co., Ltd., with registered capital of 50 million yuan, indirectly wholly owned by Jiuzhoutong. Business scope includes power generation, transmission, and solar power technology services.成立重庆九州曜阳新能源有限公司，注册资本5000万元，由九州通间接全资持股。经营范围包括发电业务、输电业务和太阳能发电技术服务。
Restructuring investment in Aoyuan Meigu (ST Meigu)重整投资奥园美谷（ST美谷）
5 · 2025-04-23 → 2026-01-28
▾
Subsidiary invests 706 million yuan to become controlling shareholder of Aoyuan Meigu, with restructuring plan approved and executed.子公司投资7.06亿元成为奥园美谷控股股东，重整计划获批准并执行完毕。
2025-04-23Jointown's wholly-owned subsidiary Jiuzhou Industrial Investment signed a restructuring investment agreement with Aoyuan Meigu (ST Meigu) to invest 673 million yuan for 360 million shares post-restructuring, aiming to become controlling shareholder.九州通全资子公司九州产投公司与奥园美谷（ST美谷）签订重整投资协议，拟出资6.73亿元取得重整后3.6亿股转增股票，意在成为控股股东。
2025-11-14A subsidiary's restructuring investment in Aoyuan Meigu (ST Meigu) was approved: Xiangyang Intermediate Court accepted the restructuring petition and appointed a administrator. Jointown will invest 706.21 million yuan for 435.93 million shares post-restructuring.全资子公司参与奥园美谷（ST美谷）重整投资获法院受理：襄阳中院裁定受理重整申请并指定管理人，九州产投拟出资7.06亿元取得重整后4.36亿股转增股票。
2025-12-18Jointown's wholly-owned subsidiary Jiuzhou Industrial Investment participated in the restructuring of Aoyuan Meigu, with the Xiangyang Intermediate People's Court approving the restructuring plan; investment consideration of about 706 million yuan for 436 million shares.九州通全资子公司九州产投参与奥园美谷重整，襄阳市中级人民法院批准重整计划；投资对价约7.06亿元获得4.36亿股。
2025-12-29Jointown announced that the restructuring plan of Aoyuan Meigu, in which its subsidiary Jiuzhou Industrial Investment participated, has been fully executed; the Xiangyang Intermediate People's Court ruled to terminate the restructuring process.九州通公告其子公司九州产投参与的奥园美谷重整计划已执行完毕，襄阳市中级人民法院裁定终结重整程序。
2026-01-28Three senior executives with Jiuzhoutong background (Su Xiling, Liu Liang, Leng Chunxia) entered the management of *ST Meigu (Ouyuan Meigu), a company undergoing restructuring, to support its medical aesthetics main business and post-restructuring operations.三位具有九州通背景的高管（苏熙凌、刘亮、冷春霞）进入重整中的*ST美谷（奥园美谷）管理层，支持其医美主业及重整后运营。
Tiankai-Jointown Biomedical Innovation Industrial Park天开-九州生物医药创新产业园
1 · 2025-04-25
▾
Construction started on biomedical innovation park in Tianjin, with total investment of ~300 million yuan.在天津启动生物医药创新产业园建设，总投资约3亿元。
2025-04-25Jointown started construction of Tiankai-Jointown Biomedical Innovation Industrial Park in Tiankai Higher Education Innovation Park, total investment ~300 million yuan, planned area 45,000 sqm, focusing on R&D, pilot and scale-up for biomedicine.九州通在天开高教科创园启动天开九州通生物医药创新产业园建设，总投资约3亿元，规划面积4.5万平方米，打造生物医药研发、小试、中试一体化载体。
Medical aesthetics segment growth医美板块增长
2 · 2025-04-28 → 2026-05-14
▾
Medical aesthetics revenue surges 120% in 2024, reaching 1.23 billion yuan in 2025, with extensive service network.医美收入2024年增长120%，2025年达12.3亿元，服务网络广泛。
2025-04-28Jointown released 2025 Q1 report: revenue 42.016 billion yuan (+3.82% YoY), net profit 970 million yuan (+80.38% YoY); medical aesthetics revenue grew 120.47% to 851 million yuan in 2024.九州通发布2025年一季报：营收420.16亿元（同比+3.82%），归母净利润9.70亿元（同比+80.38%）；2024年医美业务收入8.51亿元，同比大增120.47%。
2026-05-14Medical aesthetics segment revenue in 2025 reached 1.230 billion yuan (including tax), up 44.52% YoY, with a 3-year CAGR of 89.76%. Cooperated with 12,246 medical aesthetic service institutions, covering nearly 60% of the network.2025年医美板块实现销售收入12.30亿元（含税），同比增长44.52%，近三年复合增长率89.76%。合作医美服务机构12,246家，网络覆盖率近60%。
Huiyu Yuanhe drug approvals汇宇远禾药品批文
2 · 2025-06-04 → 2025-06-20
▾
Subsidiary Huiyu Yuanhe receives NMPA approvals for betamethasone, dexamethasone, promethazine, and bupivacaine injections.子公司汇宇远禾获得倍他米松、地塞米松、异丙嗪、布比卡因注射液等批文。
2025-06-04Subsidiary Huiyu Yuanhe (Hainan) Pharmaceutical received NMPA drug registration certificate for Betamethasone Sodium Phosphate Injection (chemical category 3, specification 1ml:4mg), valid until 2030-05-26. The product is deemed to have passed generic consistency evaluation; 2023 hospital terminal sales exceeded 220 million yuan.下属公司汇禹远和（海南）药业收到国家药监局核准签发的倍他米松磷酸钠注射液《药品注册证书》（化药3类，规格1ml:4mg），有效期至2030年5月26日。该药品视同通过仿制药一致性评价；2023年公立医疗机构终端销售额突破2.2亿元。
2025-06-20Subsidiary Huiyu Yuanhe (Hainan) Pharmaceutical received NMPA drug registration certificate for Dexamethasone Sodium Phosphate Injection (chemical category 3, specification 1ml:10.93mg), valid until 2030-06-16. National medical insurance Class A product; 2023 hospital terminal sales approached 1.2 billion yuan, up 59.27% YoY.下属公司汇禹远和（海南）药业收到国家药监局核准签发的地塞米松磷酸钠注射液《药品注册证书》（化药3类，规格1ml:10.93mg），有效期至2030年6月16日。国家医保甲类品种；2023年公立医疗机构终端销售额接近12亿元，同比增长59.27%。
Employee stock ownership plan (ESOP)员工持股计划
2 · 2025-06-18 → 2025-07-22
▾
ESOP revised and extended to 2026, third batch granted to 300 employees; prior plan expired and shares transferred.员工持股计划修订并延长至2026年，第三批授予300名员工；前期计划到期并过户。
2025-06-18Revised 2023-2025 employee stock ownership plan to 2023-2026 plan, with total fund size of 462 million yuan, holding up to 48.6 million shares (2.59% of total). Third batch to grant up to 25 million shares to 300 employees at 3.60 yuan per share. Average transfer price 9.50 yuan/share, 71.27% of repurchase average.修订2023-2025年员工持股计划为2023-2026年计划，拟筹集资金总额4.62亿元，持有股票总数不超过4860万股（占总股本2.59%）。第三批拟向不超过300名员工授予不超过2500万股，认购价格3.60元/股。平均受让价格9.50元/股，为回购均价的71.27%。
2025-07-22Jointown's third employee stock ownership plan (2022, 36-month term) expired on July 18, 2025; all 16,916,800 shares had been transferred to individual accounts, marking plan completion.九州通2022年第三期员工持股计划（36个月存续期）于2025年7月18日届满终止；所持16,916,800股股票已全部归属至持有人个人账户，计划顺利完成。
ESG & social responsibilityESG与社会责任
1 · 2025-08-16
▾
Donations and community investment activities.捐赠及社区投资活动。
2025-08-16Jointown donated 4 million RMB to Hanchuan Red Cross for local medical infrastructure upgrades.九州通向汉川市红十字会捐赠400万元，定向用于汉川市医疗卫生基础设施升级改造。
Minority investments & stakes少数股权投资与持股
1 · 2026-03-24
▾
Investments in other companies and equity stakes.对其他公司的投资及持股。
2026-03-24Investee Zhejiang Kalesi Technology Group (Kalesi Tech) listed on HKEX main board (stock code 02729.HK); investment cost RMB 26.6 million, holds 3.65% of total shares after listing.参股公司浙江凯乐士科技集团在香港联交所主板上市（股票代码02729.HK）；投资成本2660万元，持股占总股本3.65%。
Overseas expansion (Saudi Arabia & import/export)海外扩张（沙特及进出口）
2 · 2026-05-07 → 2026-05-18
▾
Established subsidiary in Saudi Arabia and Shanghai import/export company to accelerate international business.在沙特设立子公司及上海进出口公司，加速国际化业务。
2026-05-07Established Jiuzhoutong Pharmaceutical Saudi Service Company in Saudi Arabia, completing commercial registration (CR), as a wholly-owned subsidiary of Jiuzhoutong MENA Pharmaceutical Trade and Service Company, marking entry into localized operations in the Middle East.在沙特阿拉伯完成九州通医药沙特服务公司的商业注册登记，为九州通中东北非医药贸易与服务公司的全资子公司，标志着海外业务进入本地化运营阶段。
2026-05-18Shanghai Jiuzhoutong Import and Export Co., Ltd. was established in Shanghai with registered capital of 10 million yuan, wholly owned by Shanghai Jiuzhoutong Pharmaceutical Co., Ltd., accelerating international business.上海九州通进出口有限公司在上海成立，注册资本1000万元，由上海九州通医药有限公司全资控股，加速国际化业务。
